                                                ID,Text
0     Cyclin-dependent kinases (CDKs) regulate a var...
1      Abstract Background  Non-small cell lung canc...
2      Abstract Background  Non-small cell lung canc...
3     Recent evidence has demonstrated that acquired...
4     Oncogenic mutations in the monomeric Casitas B...
5     Oncogenic mutations in the monomeric Casitas B...
6     Oncogenic mutations in the monomeric Casitas B...
7     CBL is a negative regulator of activated recep...
8      Abstract Juvenile myelomonocytic leukemia (JM...
9      Abstract Juvenile myelomonocytic leukemia (JM...
10    Oncogenic mutations in the monomeric Casitas B...
11    Noonan syndrome is an autosomal dominant conge...
12    Noonan syndrome is an autosomal dominant conge...
13    Noonan syndrome is an autosomal dominant conge...
14    Oncogenic mutations in the monomeric Casitas B...
15    Noonan syndrome is an autosomal dominant conge...
16    To determine if residual cylindrical refractiv...
17    Acquired uniparental disomy (aUPD) is a common...
18    Oncogenic mutations in the monomeric Casitas B...
19    Acquired uniparental disomy (aUPD) is a common...
20     Abstract Background  Non-small cell lung canc...
21    Oncogenic mutations in the monomeric Casitas B...
22    Oncogenic mutations in the monomeric Casitas B...
23    Recent evidence has demonstrated that acquired...
24    Recent evidence has demonstrated that acquired...
25    Recent evidence has demonstrated that acquired...
26     Abstract N-myristoylation is a common form of...
27    Heterozygous mutations in the telomerase compo...
28    Sequencing studies have identified many recurr...
29    Heterozygous mutations in the telomerase compo...
30    Heterozygous mutations in the telomerase compo...
31    Sequencing studies have identified many recurr...
32    Heterozygous mutations in the telomerase compo...
33    The current World Health Organization classifi...
34    Sequencing studies have identified many recurr...
35     Abstract  DICER1 plays a critical role in mic...
36     Abstract  DICER1 plays a critical role in mic...
37    Sex cord–stromal tumors and germ-cell tumors a...
38    Sex cord–stromal tumors and germ-cell tumors a...
39    Human Dicer contains two RNase III domains (RN...
40    Human Dicer contains two RNase III domains (RN...
41    Mesenchymal cell populations contribute to mic...
42    Sex cord–stromal tumors and germ-cell tumors a...
43    Mesenchymal cell populations contribute to mic...
44    Tyrosine phosphorylation, regulated by protein...
45    The receptor protein tyrosine phosphatase T (P...
46    Introduction  Preceding hematologic disorders ...
47    The receptor protein tyrosine phosphatase T (P...
48    Metastasis is the leading cause of death for g...
49    Tyrosine phosphorylation, regulated by protein...
50    Receptor protein tyrosine phosphatase T (PTPRT...
51    Receptor protein tyrosine phosphatase T (PTPRT...
52    Protein tyrosine phosphatase ρ (PTPρ) belongs ...
53    The receptor protein tyrosine phosphatase T (P...
54    Receptor protein tyrosine phosphatase T (PTPRT...
55    The receptor protein tyrosine phosphatase T (P...
56    T-cell large granular lymphocytic (T-LGL) leuk...
57    The receptor protein tyrosine phosphatase T (P...
58    Tyrosine phosphorylation, regulated by protein...
59    Most cancers are characterized by increased ST...
60    The receptor protein tyrosine phosphatase T (P...
61    Tyrosine phosphorylation, regulated by protein...
62    Most cancers are characterized by increased ST...
63    Tyrosine phosphorylation, regulated by protein...
64    The receptor protein tyrosine phosphatase T (P...
65    Receptor protein tyrosine phosphatase T (PTPRT...
66    Tyrosine phosphorylation, regulated by protein...
67    Genes encoding components of the PI3K-Akt-mTOR...
68    Genes encoding components of the PI3K-Akt-mTOR...
69    Genes encoding components of the PI3K-Akt-mTOR...
70    Assembly of H/ACA RNPs in yeast is aided by at...
71    The cyclin-dependent protein kinases, or cdks,...
72    The Mre11 complex, composed of RAD50, NBS1 and...
73    Metastatic solid tumors are almost invariably ...
74    Mre11, Rad50, and Nbs1 function in a protein c...
75    The cyclin-dependent protein kinases, or cdks,...
76    OF THE GENERALIZATIONS TO emerge from studies ...
77    OF THE GENERALIZATIONS TO emerge from studies ...
78    The activities of cyclin D-dependent kinases s...
79    OF THE GENERALIZATIONS TO emerge from studies ...
80    The activities of cyclin D-dependent kinases s...
81    OF THE GENERALIZATIONS TO emerge from studies ...
82    Lung adenocarcinoma is comprised of distinct m...
83    Lung adenocarcinoma is comprised of distinct m...
84     Abstract RASopathies are autosomal dominant d...
85    Lung adenocarcinoma is comprised of distinct m...
86    A variety of results point to the transcriptio...
87    A variety of results point to the transcriptio...
88    The mouse double minute 2 (MDM2)–p53 interacti...
89    Multiple self-healing squamous epithelioma (MS...
90    The Loeys–Dietz syndrome is a recently describ...
91    Multiple self-healing squamous epithelioma (MS...
92    Multiple self-healing squamous epithelioma (MS...
93    Multiple self-healing squamous epithelioma (MS...
94    Very recently, heterozygous mutations in the g...
95    Malignant breast carcinoma cell lines are freq...
96    Breast cancer is the most common female malign...
97    Transforming growth factor β (TGFβ) plays a ke...
98    In many cancers, inactivating mutations in bot...
99    TbR-II (transforming growth factor b [TGF-b] t...
100   Signaling by transforming growth factor-β (TGF...
101   Melanoma patients treated with oncogenic BRAF ...
102   Identification of a high-risk disease-causing ...
103   The MSH6 gene is one of the mismatch-repair ge...
104   Human colorectal cancer cell lines are used wi...
105   The MSH6 gene is one of the mismatch-repair ge...
106   Identification of a high-risk disease-causing ...
107   A hypermutated subtype of advanced prostate ca...
108   In the United States, approximately 6.5% of al...
109   Mismatch repair (MMR) malfunction causes the a...
110   In addition to their mismatch recognition acti...
111   Identification of a high-risk disease-causing ...
112   Endometrial cancer is the most common gynecolo...
113   Endometrial cancer is the most common gynecolo...
114   EstablishedMSH6-null mice present afrequent oc...
115   Kabuki syndrome (KS) is a multiple congenital ...
116   Kabuki syndrome (KS) is a multiple congenital ...
117   The lats gene has been identified as a tumour ...
118   Screening for tumor suppressor genes in breast...
119   Screening for tumor suppressor genes in breast...
120   Background Many cases of familial renal cell c...
121   The RNA maturation is an important and complex...
122   The RNA maturation is an important and complex...
123   The splicing factor SF3B1 is the most commonly...
124   The splicing factor SF3B1 is the most commonly...
125   The RNA maturation is an important and complex...
126   The RNA maturation is an important and complex...
127   The splicing factor SF3B1 is the most commonly...
128   The RNA maturation is an important and complex...
129   The RNA maturation is an important and complex...
130   The RNA maturation is an important and complex...
131    Graphical Abstract Image for unlabelled figur...
132   Assessing the functional significance of novel...
133   The RNA maturation is an important and complex...
134   The splicing factor SF3B1 is the most commonly...
135   Mutations in genes encoding proteins involved ...
136   Precursor mRNA splicing is catalyzed by the sp...
137   Malignant mesothelioma (MM) is an aggressive n...
138   Non–small-cell lung cancer is the leading caus...
139    In contrast to other primary epidermal growth...
140   The accurate determination of perfluoroalkyl s...
141    In contrast to other primary epidermal growth...
142   Purpose: Clinical features of epidermal growth...
143   While epidermal growth factor receptor (EGFR) ...
144    In contrast to other primary epidermal growth...
145   The accurate determination of perfluoroalkyl s...
146   Somatic mutations introduced into the epiderma...
147    In contrast to other primary epidermal growth...
148   Purpose: Recently, activating mutations of the...
149   Non–small-cell lung cancer is the leading caus...
150   Alterations ofthe EGFR gene occur frequently i...
151   Purpose: Mutations in epidermal growth factor ...
152    Abstract Glioblastomas with EGFR amplificatio...
153   Many studies have reported the EGFR mutations ...
154    Abstract  Epidermal growth factor receptor (E...
155   Gefitinib is effective as first-line therapy f...
156    Abstract  Patients with epidermal growth fact...
157   There are many complex and rare mutations in t...
158   Purpose: Clinical features of epidermal growth...
159   Purpose: Clinical features of epidermal growth...
160   Epidermal growth factor receptor (EGFR) mutati...
161   Gefitinib is effective as first-line therapy f...
162   Gefitinib is effective as first-line therapy f...
163   Purpose: Epidermal growth factor receptor (EGF...
164   Oncogenic mutations in the epidermal growth fa...
165    In contrast to other primary epidermal growth...
166    Abstract  Malignant pleural effusions (MPEs) ...
167   Adrenocortical carcinoma (ACC) is a rare disea...
168   Mutations in the epidermal growth factor recep...
169   Somatic mutations in the tyrosine kinase (TK) ...
170    Abstract  The epidermal growth factor recepto...
171   Somatic mutations introduced into the epiderma...
172    Abstract  Epidermal growth factor receptor (E...
173   While epidermal growth factor receptor (EGFR) ...
174   Somatic mutations introduced into the epiderma...
175    In contrast to other primary epidermal growth...
176   While epidermal growth factor receptor (EGFR) ...
177   There are many complex and rare mutations in t...
178   In selected patients with advanced non-small c...
179   Background  Epidermal growth factor receptor (...
180   Purpose: Clinical features of epidermal growth...
181   Non-small-cell lung cancers (NSCLCs) containin...
182   Purpose: Clinical reports about responsiveness...
183   There are many complex and rare mutations in t...
184   Non–small-cell lung cancer is the leading caus...
185   ‘Classical' mutations in the EGFR tyrosine kin...
186   Mutations in the epidermal growth factor recep...
187    Abstract  Malignant pleural effusions (MPEs) ...
188   Somatic mutations in the tyrosine kinase (TK) ...
189   Gefitinib is effective as first-line therapy f...
190   A feature of many gliomas is the amplification...
191   To assess the role of various epidermal growth...
192   Purpose: Clinical features of epidermal growth...
193    In contrast to other primary epidermal growth...
194   NTRODUCTION Non–small cell lung cancers (NSCLC...
195    Abstract  Malignant pleural effusions (MPEs) ...
196   A feature of many gliomas is the amplification...
197    In contrast to other primary epidermal growth...
198   The discovery of Rous sarcoma virus (RSV) led ...
199   Kinase domain mutations of the epidermal growt...
200   Purpose: Clinical features of epidermal growth...
201    Abstract  Purpose: This study evaluated the m...
202   Purpose: Epidermal growth factor receptor (EGF...
203   Mutations in the epidermal growth factor recep...
204   We describe the landscape of somatic genomic a...
205   Cancer is a genetic disease that develops thro...
206   Somatic mutations introduced into the epiderma...
207   We describe the landscape of somatic genomic a...
208   Purpose: Clinical features of epidermal growth...
209    Summary Recent genome sequencing efforts have...
210   Non–small-cell lung cancer is the leading caus...
211   Oncogenic EGFR mutations are found in 10-35% o...
212   Mutations in the epidermal growth factor recep...
213   Purpose: Clinical features of epidermal growth...
214   NTRODUCTION Non–small cell lung cancers (NSCLC...
215   Purpose: Clinical features of epidermal growth...
216   Purpose: Clinical features of epidermal growth...
217   Signal transduction pathways are tightly contr...
218   Non–small-cell lung cancer is the leading caus...
219   Epidermal growth factor receptor (EGFR) mutati...
220   Antibodies against epidermal growth factor rec...
221    In contrast to other primary epidermal growth...
222   Introduction The epidermal growth factor recep...
223   Purpose: Clinical features of epidermal growth...
224   Purpose: Clinical features of epidermal growth...
225   Purpose: Clinical features of epidermal growth...
226   NTRODUCTION Non–small cell lung cancers (NSCLC...
227   Recently, two small-molecule kinase inhibitors...
228   There is a paucity of information about the mo...
229   Non–small-cell lung cancer is the leading caus...
230   Purpose: Clinical features of epidermal growth...
231   Non–small-cell lung cancer is the leading caus...
232   Non–small-cell lung cancer is the leading caus...
233   Cancer is a genetic disease that develops thro...
234   To assess the role of various epidermal growth...
235   Non–small-cell lung cancer is the leading caus...
236    In contrast to other primary epidermal growth...
237   Purpose: Epidermal growth factor receptor (EGF...
238   Tumor cells often subvert normal regulatory me...
239    In contrast to other primary epidermal growth...
240    Abstract  Malignant pleural effusions (MPEs) ...
241   There is a paucity of information about the mo...
242   Non-small-cell lung cancers (NSCLCs) containin...
243   Protein tyrosine kinases are important regulat...
244   There is a paucity of information about the mo...
245   Aberrant activation of the epidermal growth fa...
246   Purpose: Epidermal growth factor receptor (EGF...
247   Mutations in the epidermal growth factor recep...
248    In contrast to other primary epidermal growth...
249   ‘Classical' mutations in the EGFR tyrosine kin...
250   Purpose: Epidermal growth factor receptor (EGF...
251   Mutations in the kinase domain of epidermal gr...
252   The epidermal growth factor receptor (EGFR) is...
253   Purpose: Clinical features of epidermal growth...
254   There is a paucity of information about the mo...
255   A 70-year-old Japanese-American woman, who had...
256   EGFR is a popular therapeutic target for many ...
257   Purpose: Clinical features of epidermal growth...
258   The epidermal growth factor receptor (EGFR) is...
259   The accurate determination of perfluoroalkyl s...
260   While epidermal growth factor receptor (EGFR) ...
261    In contrast to other primary epidermal growth...
262   Non–small-cell lung cancer is the leading caus...
263   Purpose: Epidermal growth factor receptor (EGF...
264   There is a paucity of information about the mo...
265   Epidermal growth factor receptor (EGFR) is a t...
266   Purpose: Clinical features of epidermal growth...
267   Purpose: Epidermal growth factor receptor (EGF...
268   Oncogenic mutations in the epidermal growth fa...
269   Purpose: Clinical features of epidermal growth...
270   The molecular status of the epidermal growth f...
271   Protein tyrosine kinases are important regulat...
272   Purpose: Clinical features of epidermal growth...
273   Conventional wisdom holds that methylation of ...
274   Correlations among epidermal growth factor rec...
275   Purpose: Clinical features of epidermal growth...
276   Non–small-cell lung cancer is the leading caus...
277   A 60-year old Caucasian woman with a current s...
278    Abstract Colorectal cancer (CRC) is the third...
279   For 40% of pediatric T-ALL cases, underlying o...
280   For 40% of pediatric T-ALL cases, underlying o...
281   We used high-resolution array analysis to disc...
282   For 40% of pediatric T-ALL cases, underlying o...
283   For 40% of pediatric T-ALL cases, underlying o...
284   The genetic factors that determine the risk of...
285   Poorly differentiated thyroid cancer (PDTC) an...
286   In eukaryotic cells, DNA is packaged into chro...
287   In eukaryotic cells, DNA is packaged into chro...
288   Brd4 belongs to the BET family of nuclear prot...
289   NUT midline carcinoma (NMC) is a genetically d...
290   Follicular lymphoma, the most common indolent ...
291   The growing number of recently identified nega...
292   We identified CHK2 K373E as a recurrent mutati...
293   Recently, a functionally defective CHEK2 varia...
294    Abstract  Germ line mutations in CHEK2, the g...
295   Checkpoint kinase 2 (CHEK2, Chk2) emerges as a...
296   Checkpoint kinase 2 (CHEK2, Chk2) emerges as a...
297   Maintenance of genomic integrity depends on th...
298   Maintenance of genomic integrity depends on th...
299    ABSTRACT p21-activated kinases (PAKs) are ser...
300    Abstract The discovery of recurrent gene fusi...
301   Recurrent gene fusions involving oncogenic ETS...
302   Although common in hematologic and mesenchymal...
303   The serine protease TMPRSS2 gene expression wa...
304   Recurrent chromosomal rearrangements have not ...
305   The serine protease TMPRSS2 gene expression wa...
306   The DNA entry and exit points on the nucleosom...
307   The DNA entry and exit points on the nucleosom...
308   The DNA entry and exit points on the nucleosom...
309   The ETS transcription factor family is compris...
310   The ETS transcription factor family is compris...
311   The ETS transcription factor family is compris...
312   The ETS transcription factor family is compris...
313   Previous studies have shown that the promoter ...
314   The ETS transcription factor family is compris...
315   Introduction  Alterations in tyrosine kinases ...
316   INTRODUCTION Glioblastoma (GBM) is the most co...
317    Abstract Purpose  Rearranged ROS1 is a crizot...
318   Introduction  Alterations in tyrosine kinases ...
319   Echinoderm microtubule associated protein like...
320   The rapidly growing recognition of the role of...
321   Oncogenic gene fusions involving the 3’ region...
322   Chromosomal rearrangements of the gene encodin...
323   The rapidly growing recognition of the role of...
324   An increasing number of genetic alterations th...
325   The rapidly growing recognition of the role of...
326   We report the results of whole genome and tran...
327   Oncogenic gene fusions involving the 3’ region...
328   An increasing number of genetic alterations th...
329   Chromosomal rearrangements of the gene encodin...
330   Oncogenic gene fusions involving the 3’ region...
331   Echinoderm microtubule associated protein like...
332   Echinoderm microtubule associated protein like...
333   Inflammatory myofibroblastic tumor (IMT) is a ...
334   Patients with anaplastic lymphoma kinase (ALK)...
335   Kinases activated by gene fusions represent an...
336   Oncogenic gene fusions involving the 3’ region...
337   The rapidly growing recognition of the role of...
338   All cancers harbor molecular alterations in th...
339   The rapidly growing recognition of the role of...
340   The transmembrane proto-oncogene receptor tyro...
341   Acute myeloid leukemia (AML) with t(8;21) (q22...
342   Mutations in the E-cadherin (CDH1) gene are a ...
343   A 41-year-old man with no familial history of ...
344   E-cadherin is involved in the formation of cel...
345   Nonsyndromic orofacial cleft (NSOFC) is a comp...
346   E-cadherin is involved in the formation of cel...
347   To screen and characterize germline variants f...
348   E-cadherin is involved in the formation of cel...
349   Stomach cancer ranks as the third most importa...
350   In diffuse gastric carcinoma, despite common E...
351   Lynch syndrome is caused by germline mutations...
352   In pediatric patients with B-cell precursor ac...
353   Esophageal squamous cell carcinoma (ESCC) is o...
354   The transcriptional coactivator p300/CBP (CREB...
355   The transcriptional coactivator p300/CBP (CREB...
356   We report on the fusion of the monocytic leuke...
357   The transcriptional co-activators and histone ...
358   The p300 protein shows a striking homology wit...
359   The EP300 protein is a histone acetyltransfera...
360   Esophageal squamous cell carcinoma (ESCC) is o...
361   Hypoxia inducible factors (HIFs) are transcrip...
362   Hypoxia inducible factors (HIFs) are transcrip...
363   Hypoxia inducible factors (HIFs) are transcrip...
364   Hypoxia inducible factors (HIFs) are transcrip...
365   Hypoxia inducible factors (HIFs) are transcrip...
366   Introduction  Hypoxia-inducible factors (HIFs)...
367    Abstract Deletion of the von Hippel-Lindau tu...
368   Hypoxia inducible factors (HIFs) are transcrip...
369   p53 is a sequence-specific transcription facto...
370   Mutations in the p53 tumor suppressor are the ...
371   Inheritance of germ-line mutant alleles of BRC...
372   Melanoma cell lines and normal human melanocyt...
373   Genotoxic stress triggers a rapid translocatio...
374   Critical determinants of DNA recognition by p5...
375   The Li-Fraumeni Syndrome (LFS) is a rare, domi...
376   The tumor suppressor protein p53 is a transcri...
377   p53 mutations are mostly single amino acid cha...
378   The p53 protein is a sequence-specific transcr...
379   Under conditions of genotoxic stress, human p5...
380   The tumour suppressor gene p53 is frequently m...
381    Summary The present study represents a contin...
382   The tumor suppressor p53, a 393-amino acid tra...
383   Both sequence-specific DNA binding and exonucl...
384   Inheritance of germ-line mutant alleles of BRC...
385    Abstract Exposure to herbal remedies containi...
386   Both inactivation of p53 function and loss of ...
387   Suppression of tumor cell growth by p53 result...
388   Imprinted genes, many of which are involved in...
389   Tumor suppressor p53-dependent apoptosis is th...
390   TP53gene alterations may result in the gain of...
391   Tumor suppressor p53-dependent apoptosis is th...
392   Inheritance of germ-line mutant alleles of BRC...
393   The tumor suppressor protein p53 is a transcri...
394   Critical determinants of DNA recognition by p5...
395   TP53 is the most commonly mutated gene in head...
396   Tumor suppressor p53-dependent apoptosis is th...
397   The tumor suppressor p53 is known as the “guar...
398   Li Fraumeni syndrome (LFS) is a rare familial ...
399   Inheritance of germ-line mutant alleles of BRC...
400   The transcription factor and tumor suppressor ...
401   Tumor suppressor p53-dependent apoptosis is th...
402   Mutational hotspots indicate selective pressur...
403   Mutation causes inactivation of ‘p53’ tumor su...
404   The tumor suppressor protein p53 is a transcri...
405   The tumor suppressor protein p53 is inactivate...
406   Mutations of the sequence-specific master regu...
407   Somatic TP53 mutations have been described in ...
408   The p53 protein plays an important role in can...
409   p53 protein is a transcription factor involved...
410   Tumor suppressor p53-dependent apoptosis is th...
411   The p53 gene is the most commonly mutated targ...
412   Mutations in the p53 tumor suppressor are the ...
413   Critical determinants of DNA recognition by p5...
414   Mutations of the sequence-specific master regu...
415   The tumor suppressor protein p53 is a transcri...
416   The effects of chlorpromazine on various prope...
417   Approximately half of all hereditary breast ca...
418   Many p53 missense mutations possess dominant-n...
419   Mortality of patients with head and neck squam...
420   Down-regulation of p53 expression has been fou...
421   Critical determinants of DNA recognition by p5...
422   The tumor suppressor protein p53 is a transcri...
423   The Li-Fraumeni Syndrome (LFS) is a rare, domi...
424   The Li-Fraumeni Syndrome (LFS) is a rare, domi...
425   Under conditions of genotoxic stress, human p5...
426   Transcription factor p53 plays a critical role...
427   Mutations of the sequence-specific master regu...
428   Mutations in the p53 tumor suppressor are the ...
429   1. Introduction Cancer is commonly considered ...
430   The human p53 gene encodes a nuclear protein t...
431   The tumor suppressor protein p53 is a transcri...
432   The functional activity of the p53 tumor suppr...
433   Background: Transforming growth factor-beta (T...
434   Many p53 missense mutations possess dominant-n...
435   Many p53 missense mutations possess dominant-n...
436   Both sequence-specific DNA binding and exonucl...
437   Tumor suppressor p53-dependent apoptosis is th...
438    Abstract Purpose  Adrenocortical carcinoma (A...
439    Abstract The loss of wild type p53 tumor supp...
440   The tumor suppressor p53, a 393-amino acid tra...
441   Specific changes in gene expression during can...
442   Abstract Pro-oncogenic properties of mutant p5...
443   Human T-cell leukemia virus type 1 (HTLV-1) is...
444   From its modest beginnings in 1979, as a trans...
445   Both sequence-specific DNA binding and exonucl...
446   Mutations of the sequence-specific master regu...
447   p73, a close homolog of p53 tumor suppressor, ...
448   null The transcription factor and tumor suppre...
449   The tumor suppressor protein p53 is a transcri...
450   Mutations in the p53 tumor suppressor are the ...
451   Both sequence-specific DNA binding and exonucl...
452    Abstract Purpose  Adrenocortical carcinoma (A...
453   The tumor suppressor protein p53 acts as a tra...
454   Pediatric choroid plexus carcinomas (CPC) and ...
455   The PTTG1-binding factor (PBF) is a transformi...
456   Inheritance of germ-line mutant alleles of BRC...
457   TP53 is a transcription factor that plays a pi...
458   The tumor suppressor p53 has defined roles in ...
459   Attenuation of the p53 protein is one of the m...
460   The tumor suppressor protein p53 is a transcri...
461   Tumor suppressor p53-dependent apoptosis is th...
462   ZBP-89 is a widely expressed Krüppeltype zinc ...
463    Abstract Chronic myelogenous leukemia (CML) i...
464   The transcription factor and tumor suppressor ...
465   The Li-Fraumeni Syndrome (LFS) is a rare, domi...
466   Half of all human cancers lose p53 function by...
467    Abstract Purpose  Adrenocortical carcinoma (A...
468   Tumor suppressor p53-dependent apoptosis is th...
469   Tumor suppressor p53-dependent apoptosis is th...
470   Under conditions of genotoxic stress, human p5...
471   Many p53 missense mutations possess dominant-n...
472   The tumor suppressor protein p53 is a transcri...
473   The p53 tumor suppressor is a transcription fa...
474   Half of all human cancers lose p53 function by...
475   Mutational hotspots indicate selective pressur...
476    Abstract Purpose  Adrenocortical carcinoma (A...
477   Inheritance of germ-line mutant alleles of BRC...
478   Tumor suppressor p53-dependent apoptosis is th...
479   Somatic TP53 mutations have been described in ...
480   Mutations in the p53 tumor suppressor are the ...
481   TP53 is the most commonly mutated gene in head...
482    Abstract Purpose  Adrenocortical carcinoma (A...
483   The transcription factor and tumor suppressor ...
484   The transcription factor and tumor suppressor ...
485   Both sequence-specific DNA binding and exonucl...
486   Tumor suppressor p53-dependent apoptosis is th...
487    Abstract Purpose  Adrenocortical carcinoma (A...
488   Genotoxic stress triggers a rapid translocatio...
489   p53 mutation is associated with “gain-of-funct...
490   Tumor suppressor p53-dependent apoptosis is th...
491   ZBP-89 is a widely expressed Krüppeltype zinc ...
492   Half of all human cancers lose p53 function by...
493   Tumor suppressor p53-dependent apoptosis is th...
494   More than half of all human cancers are associ...
495   Inheritance of germ-line mutant alleles of BRC...
496   The tumor suppressor protein p53 is a transcri...
497   Both sequence-specific DNA binding and exonucl...
498    Abstract Over 1000 different mutants of the t...
499   Tumor suppressor p53-dependent apoptosis is th...
500   Many p53 missense mutations possess dominant-n...
501    Abstract Purpose  Adrenocortical carcinoma (A...
502   Mutations of the sequence-specific master regu...
503   Tumor suppressor p53-dependent apoptosis is th...
504   Many p53 missense mutations possess dominant-n...
505   ntroduction p53 mutations are common in lung c...
506   Tumor suppressor p53-dependent apoptosis is th...
507   The p53 tumor suppressor gene acquires missens...
508   Tumor suppressor p53-dependent apoptosis is th...
509   Tumor suppressor p53 is a sequence-specific DN...
510   p53 is the most frequently mutated tumor-suppr...
511   Tumor-derived mutant forms of p53 compromise i...
512   The tumor suppressor gene p53 has been implica...
513   Critical determinants of DNA recognition by p5...
514   The tumor suppressor p53 is known as the “guar...
515   Mutations in the p53 tumor suppressor are the ...
516   The tumor suppressor protein p53 is a transcri...
517   Inheritance of germ-line mutant alleles of BRC...
518   Mutations of the sequence-specific master regu...
519   Mutation of the tumor suppressor TP53 gene occ...
520   The PTTG1-binding factor (PBF) is a transformi...
521   The transcription factor and tumor suppressor ...
522   The ability of p53 to induce apoptosis plays a...
523   Mutations in the p53 tumor suppressor are the ...
524   The tumor suppressor p53, a 393-amino acid tra...
525    Abstract Mutations at the tumour suppressor g...
526   Both sequence-specific DNA binding and exonucl...
527   Reporter gene transactivation by human p53 is ...
528   Mutations in the p53 tumor suppressor are the ...
529   Hepatocellular carcinoma (HCC) may develop acc...
530   The tumor suppressor protein p53 is a transcri...
531   p53 is a sequence-specific transcription facto...
532   Introduction  Inhibition of PARP1 induces synt...
533   p53 binding protein 1 (53BP1) was identified i...
534    Abstract To investigate genetic alterations i...
535   Activation of the canonical TGF-β signaling pa...
536   Smad proteins mediate transforming growth fact...
537   Smad proteins mediate transforming growth fact...
538   Smad proteins mediate transforming growth fact...
539   Transforming growth factor- (TGF-) plays a com...
540   Activation of the canonical TGF-β signaling pa...
541   Ligand-induced phosphorylation of the receptor...
542   Transforming growth factor β (TGF-β) superfami...
543   Activation of the canonical TGF-β signaling pa...
544   Activation of the canonical TGF-β signaling pa...
545   Smad proteins mediate transforming growth fact...
546   Ligand-induced phosphorylation of the receptor...
547   Ligand-induced phosphorylation of the receptor...
548   Ligand-induced phosphorylation of the receptor...
549   Ligand-induced phosphorylation of the receptor...
550   Activation of the canonical TGF-β signaling pa...
551   Smad proteins mediate transforming growth fact...
552   Ligand-induced phosphorylation of the receptor...
553   Hub proteins are connected through binding int...
554   Hub proteins are connected through binding int...
555   Hub proteins are connected through binding int...
556   Activation of the canonical TGF-β signaling pa...
557    Abstract To investigate genetic alterations i...
558   Smad proteins are the key effectors of the tra...
559   Members of the transforming growth factor-beta...
560   Hub proteins are connected through binding int...
561   Hub proteins are connected through binding int...
562   Hub proteins are connected through binding int...
563   Activation of the canonical TGF-β signaling pa...
564   Hub proteins are connected through binding int...
565   Smad proteins are the key effectors of the tra...
566   Activation of the canonical TGF-β signaling pa...
567   Hub proteins are connected through binding int...
568   Hub proteins are connected through binding int...
569   Hub proteins are connected through binding int...
570   Hub proteins are connected through binding int...
571   Transforming growth factor β (TGFβ) activates ...
572   Transforming growth factor β (TGFβ) activates ...
573   Activation of the canonical TGF-β signaling pa...
574   Smad proteins are the key effectors of the tra...
575   Activation of the canonical TGF-β signaling pa...
576   The Smad4/DPC4 tumour suppressor1 is inactivat...
577   Juvenile polyposis (JP) is an autosomal domina...
578   Transforming growth factor-beta (TGF-beta) sup...
579   Activation of the canonical TGF-β signaling pa...
580   The Smad4/DPC4 tumour suppressor1 is inactivat...
581   The formation of protein complexes between pho...
582   Smad proteins mediate transforming growth fact...
583   The Smad4/DPC4 tumour suppressor1 is inactivat...
584   Transforming growth factor-beta (TGF-beta) sup...
585   Activation of the canonical TGF-β signaling pa...
586   Transforming growth factor-beta (TGF-beta) sup...
587   Transforming growth factor-beta (TGF-beta) sup...
588   Smad proteins mediate transforming growth fact...
589   Although colorectal mucinous adenocarcinomas (...
590   Smad proteins mediate transforming growth fact...
591   Ligand-induced phosphorylation of the receptor...
592   Juvenile polyposis (JP) is an autosomal domina...
593   The formation of protein complexes between pho...
594   The Smad4/DPC4 tumour suppressor1 is inactivat...
595   Transforming growth factor-beta (TGF-beta) sup...
596   Transforming growth factor-beta (TGF-beta) sup...
597   TGFβ signaling Smads (Smad2, 3, and 4) were su...
598   Ligand-induced phosphorylation of the receptor...
599   Juvenile polyposis (JP) is an autosomal domina...
600   Ligand-induced phosphorylation of the receptor...
601   Although colorectal mucinous adenocarcinomas (...
602   Although colorectal mucinous adenocarcinomas (...
603   Smad proteins are the key effectors of the tra...
604   Mutational hotspots indicate selective pressur...
605   The Smad4/DPC4 tumour suppressor1 is inactivat...
606   Smad proteins mediate transforming growth fact...
607   INTRODUCTION Transforming growth factor β (TGF...
608   The recent elucidation of the genomic landscap...
609    ABSTRACT Glioblastoma multiforme (GBM) is a f...
610   Many human tumors harbor mutations that result...
611   Mutations in genes that lie in the retinoblast...
612   Cancers arise owing to mutations in a subset o...
613   Autosomal recessive primary microcephaly (MCPH...
614   Recurrent chromosomal aberrations in hematopoi...
615   Cancer genome characterization efforts now pro...
616   Background  Melanoma is a heterogeneous tumor ...
617   Deletion of ovarian carcinoma 2/disabled homol...
618   Cancer genome characterization efforts now pro...
619   Fbw7 physically interacts with SKP1 by anti ta...
620   Cyclin E, one of the activators of the cyclin-...
621   T cell acute lymphoblastic leukemia (T-ALL) is...
622   T-cell acute lymphocytic leukemia (T-ALL) is a...
623   Cancer genome characterization efforts now pro...
624   Cancer genome characterization efforts now pro...
625   Cancer genome characterization efforts now pro...
626   Fbw7 (F-box WD40 protein 7) is a major tumour ...
627   Fbw7 is the substrate recognition component of...
628   γ-secretase inhibitors (GSIs) can block NOTCH ...
629   Tumor suppressors with widespread impact on ca...
630   Cancer genome characterization efforts now pro...
631   This study focused on a cell cycle regulatory ...
632   Background  Melanoma is a heterogeneous tumor ...
633   FBXW7 encodes the substrate recognition compon...
634   Aberrant activation of the canonical Wnt/β-cat...
635   The cell cycle inhibitor p21CDKN1A induces cel...
636   INTRODUCTION Loss of control of the mammalian ...
637   Several groups have recently isolated and char...
638   Introduction A series of cyclin and cyclin-dep...
639   Context:  Typical nonfamilial (sporadic) parat...
640   Relationship between the p27Kip1 (here after r...
641   The CDKN1B gene encodes the cyclin-dependent k...
642   Coding mutations of the CDKN2A gene on chromos...
643   ABSTRACT: Germline mutations of the CDKN2A gen...
644   Inherited mutations affecting the INK4a/ARF lo...
645   Inherited mutations affecting the INK4a/ARF lo...
646   Inherited mutations affecting the INK4a/ARF lo...
647   BACKGROUND: Point mutations in the tumor suppr...
648   The p16 gene is located in chromosome 9p21, a ...
649   Inherited mutations affecting the INK4a/ARF lo...
650   Inherited mutations affecting the INK4a/ARF lo...
651    Abstract The tumor suppressor p16INK4A with e...
652   Inherited mutations affecting the INK4a/ARF lo...
653   ABSTRACT: Germline mutations of the CDKN2A gen...
654   Inherited mutations affecting the INK4a/ARF lo...
655   Inherited mutations affecting the INK4a/ARF lo...
656   BACKGROUND: Point mutations in the tumor suppr...
657   BACKGROUND: Point mutations in the tumor suppr...
658   BACKGROUND: Point mutations in the tumor suppr...
659   BACKGROUND: Point mutations in the tumor suppr...
660   BACKGROUND: Point mutations in the tumor suppr...
661   Inherited mutations affecting the INK4a/ARF lo...
662   Inherited mutations affecting the INK4a/ARF lo...
663   Missense amino-acid (AA) substitutions may or ...
664   Determining how somatic copy-number alteration...
665   Inherited mutations affecting the INK4a/ARF lo...
666   Inherited mutations in the CDKN2A/INK4a/MTS1 t...
667   Inherited mutations affecting the INK4a/ARF lo...
668   Inherited mutations affecting the INK4a/ARF lo...
669   Inherited mutations affecting the INK4a/ARF lo...
670   Background: A common missense variant of the C...
671   Inherited mutations affecting the INK4a/ARF lo...
672   BACKGROUND: Point mutations in the tumor suppr...
673   Inherited mutations affecting the INK4a/ARF lo...
674   BACKGROUND: Point mutations in the tumor suppr...
675   Inherited mutations affecting the INK4a/ARF lo...
676   BACKGROUND: Point mutations in the tumor suppr...
677   The INK4a/ARF tumor suppressor locus is implic...
678   Inherited mutations affecting the INK4a/ARF lo...
679   BACKGROUND: Point mutations in the tumor suppr...
680   ABSTRACT: Germline mutations of the CDKN2A gen...
681   BACKGROUND: Point mutations in the tumor suppr...
682   The solution structure of the tumor suppressor...
683    Abstract The tumor suppressor p16INK4A with e...
684   ABSTRACT: Germline mutations of the CDKN2A gen...
685   Inherited mutations affecting the INK4a/ARF lo...
686   Inherited mutations affecting the INK4a/ARF lo...
687   Inherited mutations affecting the INK4a/ARF lo...
688   Cell division is controlled by a series of pos...
689   Inherited mutations affecting the INK4a/ARF lo...
690   BACKGROUND: Point mutations in the tumor suppr...
691   Inherited mutations in the CDKN2A/INK4a/MTS1 t...
692   Cell division is controlled by a series of pos...
693   Cell division is controlled by a series of pos...
694   Introduction  Since the first proposal of a po...
695   Introduction  Since the first proposal of a po...
696   Multiple myeloma (MM) is an incurable plasma c...
697   Familial renal cell carcinoma (RCC) is genetic...
698   Familial renal cell carcinoma (RCC) is genetic...
699   The molecular pathogenesis of sporadic parathy...
700   Familial renal cell carcinoma (RCC) is genetic...
701   Deletions of chromosome 1 have been described ...
702   ASXL1 is mutated/deleted with high frequencies...
703   Purpose: Mutations associated with resistance ...
704   We assessed somatic alleles of six receptor ty...
705    Abstract Lapatinib, a dual tyrosine kinase in...
706   Overexpression of the ERBB2 kinase is observed...
707   Resistance to HER2-targeted therapies remains ...
708   The mutant c-erbB-2 protein with Glu instead o...
709   Functional characterization of cancer-associat...
710   Purpose: Mutations associated with resistance ...
711   Cancer genome sequencing is identifying new ge...
712   Purpose: Mutations associated with resistance ...
713   Amplification and overexpression of the proto-...
714   Purpose: Mutations associated with resistance ...
715   Purpose: Mutations associated with resistance ...
716   Abstract' ' ' ' Purpose: Somatic mutations in ...
717   Purpose: Mutations associated with resistance ...
718   Functional characterization of cancer-associat...
719   Protein-tyrosine kinases (PTKs)3 play a centra...
720   A 58-year-old woman was evaluated at our insti...
721   Despite the ongoing “war on cancer,” cancer re...
722   Purpose: Mutations associated with resistance ...
723   Purpose: Mutations associated with resistance ...
724   We assessed somatic alleles of six receptor ty...
725    Abstract Human epidermal growth factor recept...
726   We encountered a family of Japanese descent in...
727   Mutational hotspots indicate selective pressur...
728    Abstract  ErbB2 overexpression in breast tumo...
729   Individuals with gallbladder carcinoma (GBC), ...
730   We assessed somatic alleles of six receptor ty...
731   We assessed somatic alleles of six receptor ty...
732   Trastuzumab is a monoclonal antibody against H...
733   Overexpression of the ERBB2 kinase is observed...
734   Purpose: Mutations associated with resistance ...
735   ErbB4 is a member of the ErbB family of recept...
736   Purpose: Mutations associated with resistance ...
737   Functional characterization of cancer-associat...
738    Abstract Lapatinib, a dual tyrosine kinase in...
739   The epidermal growth factor receptor (EGFR) ha...
740   Functional characterization of cancer-associat...
741   The HER2/neu oncogene is an important diagnost...
742   Overexpression of the ERBB2 kinase is observed...
743   Trastuzumab is a monoclonal antibody against H...
744   The antibody trastuzumab is approved for treat...
745   Overexpression of the ERBB2 kinase is observed...
746   Purpose: Mutations associated with resistance ...
747   Functional characterization of cancer-associat...
748   Individuals with gallbladder carcinoma (GBC), ...
749   Functional characterization of cancer-associat...
750   Purpose: Mutations associated with resistance ...
751   Overexpression of the ERBB2 kinase is observed...
752   The mutant c-erbB-2 protein with Glu instead o...
753   Purpose: Mutations associated with resistance ...
754   A 58-year-old woman was evaluated at our insti...
755   Purpose: Mutations associated with resistance ...
756   The HER2 receptor tyrosine kinase is a driver ...
757   We assessed somatic alleles of six receptor ty...
758    Abstract Human epidermal growth factor recept...
759    Abstract Lapatinib, a dual tyrosine kinase in...
760    Abstract Lapatinib, a dual tyrosine kinase in...
761   We assessed somatic alleles of six receptor ty...
762   We assessed somatic alleles of six receptor ty...
763   Purpose: Mutations associated with resistance ...
764   Protein-tyrosine kinases (PTKs)3 play a centra...
765   Purpose: Mutations associated with resistance ...
766   Overexpression of the ERBB2 kinase is observed...
767   We assessed somatic alleles of six receptor ty...
768   Functional characterization of cancer-associat...
769   A 58-year-old woman was evaluated at our insti...
770   Resistance to HER2-targeted therapies remains ...
771   Introduction HER2/Neu (ErbB2) is a member of t...
772   The human epidermal growth factor receptor (HE...
773   Introduction Epidermal growth factor receptor ...
774   The human epidermal growth factor receptor (HE...
775   The human epidermal growth factor receptor (HE...
776   The human epidermal growth factor receptor (HE...
777   The human epidermal growth factor receptor (HE...
778   Abstract HER3 is a member of the HER (EGFR/Erb...
779   The human epidermal growth factor receptor (HE...
780   Introduction Epidermal growth factor receptor ...
781   The human epidermal growth factor receptor (HE...
782   The human epidermal growth factor receptor (HE...
783   Tyrosine phosphorylation is important in signa...
784   Purpose: To identify druggable oncogenic fusio...
785   Recent efforts to comprehensively characterize...
786   Tyrosine phosphorylation is important in signa...
787   Recent efforts to comprehensively characterize...
788   Recent efforts to comprehensively characterize...
789   Recent efforts to comprehensively characterize...
790   Tyrosine phosphorylation is important in signa...
791   Resistance to HER2-targeted therapies remains ...
792   Recent efforts to comprehensively characterize...
793   Purpose: To identify druggable oncogenic fusio...
794   Recent efforts to comprehensively characterize...
795   Resistance to HER2-targeted therapies remains ...
796   Resistance to HER2-targeted therapies remains ...
797   The ErbB/EGFR/HER family of kinases consists o...
798   Tyrosine phosphorylation is important in signa...
799   Tyrosine phosphorylation is important in signa...
800   Tyrosine phosphorylation is important in signa...
801   Recent efforts to comprehensively characterize...
802   Tyrosine phosphorylation is important in signa...
803   Introduction  Platinum-based chemotherapy has ...
804   Introduction  Platinum-based chemotherapy has ...
805   The increasing application of gene panels for ...
806   Introduction  Platinum-based chemotherapy has ...
807   Introduction  Platinum-based chemotherapy has ...
808   The increasing application of gene panels for ...
809   The increasing application of gene panels for ...
810   Introduction  Platinum-based chemotherapy has ...
811   The increasing application of gene panels for ...
812   The increasing application of gene panels for ...
813   The increasing application of gene panels for ...
814   Introduction  Platinum-based chemotherapy has ...
815   The increasing application of gene panels for ...
816   The increasing application of gene panels for ...
817   Introduction  Platinum-based chemotherapy has ...
818   The increasing application of gene panels for ...
819   The increasing application of gene panels for ...
820   Introduction  Platinum-based chemotherapy has ...
821   The increasing application of gene panels for ...
822   Fanconi anemia (FA) is a genetic disease chara...
823   BRCA1 interacts in vivo with a novel protein, ...
824   The BRCA1 associated C-terminal helicase (BACH...
825   Recent predictions of risks of developing a co...
826   We showed in this study that cells deficient o...
827   BRIP1 is a DNA helicase that directly interact...
828   BRCA1 interacts in vivo with a novel protein, ...
829    Abstract  Known gene mutations account for ap...
830   Mutation of the XPB gene in humans gives rise ...
831   Recently, it has been reported that biallelic ...
832   Xeroderma pigmentosum (XP) complementation gro...
833   In addition to its well-documented effects on ...
834   Fanconi anemia (FA) is a rare genomic instabil...
835   Xeroderma pigmentosum (XP) complementation gro...
836   Recently, it has been reported that biallelic ...
837   The BCR-ABL oncogene is generated by the Phila...
838    Abstract  Mutations in the Bcr-Abl kinase dom...
839    Abstract  Mutations in the Bcr-Abl kinase dom...
840    Abstract  Mutations in the Bcr-Abl kinase dom...
841   In 1960, Nowell and Hungerford identified an a...
842   Discovery of imatinib mesylate (IM) as the tar...
843    Abstract  Mutations in the Bcr-Abl kinase dom...
844   In patients with Philadelphia-positive acute l...
845   Sequential treatment with different tyrosine k...
846    Abstract  Mutations in the Bcr-Abl kinase dom...
847   Kinase domain (KD) mutations of Bcr-Abl interf...
848   Protein kinases targeted by small-molecule inh...
849    Abstract  Mutations in the Bcr-Abl kinase dom...
850    Abstract  Mutations in the Bcr-Abl kinase dom...
851   The resistance to the tyrosine kinase inhibito...
852    Abstract  Mutations in the Bcr-Abl kinase dom...
853   Mutations in the Bcr-Abl kinase domain are a f...
854   Point mutations of the Bcr-Abl kinase domain (...
855    Abstract  Mutations in the Bcr-Abl kinase dom...
856    Abstract  Mutations in the Bcr-Abl kinase dom...
857   To realize the full potential of targeted prot...
858   Development of resistance to imatinib mesylate...
859   To realize the full potential of targeted prot...
860    Abstract  Mutations in the Bcr-Abl kinase dom...
861    Abstract  Mutations in the Bcr-Abl kinase dom...
862   For patients with chronic myeloid leukemia who...
863   The CCAAT/enhancer binding protein α (C/EBPα) ...
864   TMPRSS2-ERG gene fusions occur in about 50% of...
865   Sarcomas constitute some of the most aggressiv...
866   Thet(16;21)(pll;q22)translocationIsa recurrent...
867   A step toward the molecular classification of ...
868   A new variant of the HLA-A*010101 allele desig...
869   The transplantation of haematopoietic stem cel...
870    Abstract  Characterization of a novel HLA-B n...
871   Introduction  Pediatric high-grade gliomas (HG...
872   Purpose: Platelet-derived growth factor recept...
873   The FIP1L1-PDGFRA fusion is seen in a fraction...
874   Purpose: Platelet-derived growth factor recept...
875   Activating mutations in the platelet-derived g...
876   Gene rearrangement in the form of an intrageni...
877   Activating mutations in the platelet-derived g...
878   Purpose: Platelet-derived growth factor recept...
879   The FIP1L1-PDGFRA fusion is seen in a fraction...
880   Purpose: Platelet-derived growth factor recept...
881   Introduction  Pediatric high-grade gliomas (HG...
882   Gastrointestinal stromal tumors (GISTs) common...
883   The FIP1L1-PDGFRA fusion is seen in a fraction...
884   Germline PDGFRA mutations cause multiple heter...
885   Purpose: Platelet-derived growth factor recept...
886   Activating mutations in the platelet-derived g...
887   Activating mutations in the platelet-derived g...
888   Our previous report showed that platelet-deriv...
889   The pathogenesis of most gastrointestinal stro...
890   The FIP1L1-PDGFRA fusion is seen in a fraction...
891   Activating mutations in the platelet-derived g...
892   Purpose: Platelet-derived growth factor recept...
893   Gastrointestinal stromal tumors (GISTs) common...
894   The FIP1L1-PDGFRA fusion is seen in a fraction...
895   Gene rearrangement in the form of an intrageni...
896   Purpose: Platelet-derived growth factor recept...
897   Activating mutations in platelet-derived growt...
898   Purpose: Platelet-derived growth factor recept...
899   To determine the potential of crenolanib, a po...
900   Gastrointestinal stromal tumors (GISTs) common...
901   Gastrointestinal stromal tumors (GISTs) common...
902   Gastrointestinal stromal tumors (GISTs) common...
903   We identified two patients with a t(2;4)(p24;q...
904   The FIP1L1-PDGFRA fusion is seen in a fraction...
905   Purpose: Platelet-derived growth factor recept...
906   Activating mutations in the platelet-derived g...
907   Purpose: Platelet-derived growth factor recept...
908   Purpose: Platelet-derived growth factor recept...
909   To determine the potential of crenolanib, a po...
910   Purpose: Platelet-derived growth factor recept...
911   Introduction  Pediatric high-grade gliomas (HG...
912   Long-term survival for children with diffuse i...
913   Activating mutations in the platelet-derived g...
914   Gastrointestinal stromal tumors (GISTs) common...
915   Gastrointestinal stromal tumors (GISTs) common...
916   To determine the potential of crenolanib, a po...
917   Hypereosinophilic syndrome (HES) and chronic e...
918   The FIP1L1-PDGFRA fusion is seen in a fraction...
919   Activating mutations in platelet-derived growt...
920   Introduction  Pediatric high-grade gliomas (HG...
921   Gastrointestinal stromal tumors (GISTs) common...
922   We identified two patients with a t(2;4)(p24;q...
923   Gastrointestinal stromal tumors (GISTs) common...
924   Gastrointestinal stromal tumor (GIST) is the m...
925   Chronic myeloid leukaemia (CML) is characteriz...
926   To determine the potential of crenolanib, a po...
927   We identified two patients with a t(2;4)(p24;q...
928   Purpose: Platelet-derived growth factor recept...
929   Introduction  Pediatric high-grade gliomas (HG...
930   Activating mutations in the platelet-derived g...
931   KANK1-PDGFRB is a fusion gene generated by the...
932   To identify a new idiopathic basal ganglia cal...
933    Abstract  We describe a new PDGFRB fusion ass...
934   Chronic myeloproliferative disorders (CMPD) ar...
935   Acquired constitutive activation of protein ty...
936   Acquired constitutive activation of protein ty...
937   We describe the fusion of TP53BP1 to PDGFRB in...
938    Abstract  A large number of alterations in ge...
939   Chronic myeloproliferative disorders (CMPD) ar...
940   The advent of tyrosine kinase inhibitors (TKI)...
941   Chronic myelomonocytic leukemia (CMML) is a my...
942   Metastatic breast cancer (MBC) is an incurable...
943   To identify a new idiopathic basal ganglia cal...
944   Eosinophilia is common in myeloproliferative d...
945   Acquired constitutive activation of protein ty...
946    Abstract Infantile myofibromatosis (IM) is th...
947   Fusion genes involving tyrosine kinases (TKs) ...
948   Chronic myeloproliferative disorders (CMPD) ar...
949    Abstract Chromosomal translocations involving...
950   We report the fusion of the Huntingtin interac...
951   Eosinophilia is common in myeloproliferative d...
952   ETV6-PDGFRB (also called TEL-PDGFRB) and FIP1L...
953   Penttinen syndrome is a distinctive disorder c...
954   TARP syndrome, comprising Talipes equinovarus,...
955   RBM10 is an RNA binding protein and alternativ...
956   Notch signaling regulates cell specification a...
957    Abstract Mutations in KDM5C are an important ...
958    Abstract Mutations in KDM5C are an important ...
959    Abstract Mutations in KDM5C are an important ...
960   Currently, few prognostic factors are availabl...
961    Abstract Mutations in KDM5C are an important ...
962   The crucial role of recurrent gene fusions in ...
963   Recent studies have identified somatic ESR1 mu...
964   The antagonist activity of antiestrogens is du...
965   The estrogen receptor complex is a known trans...
966   Seventy percent of breast cancers express estr...
967   The estrogen receptor (ER) belongs to a large ...
968   Recent studies have identified somatic ESR1 mu...
969   To characterize patient-derived xenografts (PD...
970   Breast cancer is the most prevalent cancer in ...
971   The estrogen receptor complex is a known trans...
972   Recent studies have identified somatic ESR1 mu...
973   The crucial role of recurrent gene fusions in ...
974   Seventy percent of breast cancers express estr...
975   Recent studies have identified somatic ESR1 mu...
976   We undertook this study to determine the preva...
977   Seventy percent of breast cancers express estr...
978    Abstract The discovery of recurrent gene fusi...
979   Gene fusions involving the erythroblast transf...
980   Sarcomas constitute some of the most aggressiv...
981    Abstract Some familial platelet disorders are...
982   We report germline missense mutations in ETV6 ...
983   Congenital fibrosarcoma (CFS) and cellular mes...
984    Abstract Some familial platelet disorders are...
985   We report germline missense mutations in ETV6 ...
986    Abstract Some familial platelet disorders are...
987   The myeloproliferative disorders (MPD) are chr...
988   ETV6-NTRK3 (EN), a chimeric tyrosine kinase ge...
989   Tuberous sclerosis complex (TSC) is an autosom...
990   More than 50% of transitional cell carcinomas ...
991   Tuberous sclerosis complex is a disease caused...
992   More than 50% of transitional cell carcinomas ...
993   Tuberous sclerosis complex (TSC) is an autosom...
994   More than 50% of transitional cell carcinomas ...
995   Tuberous sclerosis complex (TSC) is an autosom...
996   More than 50% of transitional cell carcinomas ...
997   Tuberous sclerosis complex (TSC) is an autosom...
998   Tuberous sclerosis complex (TSC) is an autosom...
999   Along-standing problem in oncology is the vari...
1000  More than 50% of transitional cell carcinomas ...
1001  Tuberous sclerosis complex (TSC) is an autosom...
1002  Tuberous sclerosis complex (TSC) is an autosom...
1003  Tuberous sclerosis complex (TSC) is an autosom...
1004  More than 50% of transitional cell carcinomas ...
1005  Tuberous sclerosis complex (TSC) is an autosom...
1006  Tuberous sclerosis complex (TSC) is an autosom...
1007  Tuberous sclerosis complex (TSC) is an autosom...
1008  Tuberous sclerosis complex (TSC) is an autosom...
1009  Interrogate the impact of IKZF1 deletion on th...
1010  Tuberous sclerosis complex (TSC) is an autosom...
1011  Tuberous sclerosis complex (TSC) is an autosom...
1012  Tuberous sclerosis complex (TSC) is an autosom...
1013  Tuberous sclerosis complex (TSC) is an autosom...
1014  Tuberous sclerosis complex (TSC) is an autosom...
1015   SUMMARY mTORC1 promotes cell growth in respon...
1016  Tuberous sclerosis complex (TSC) is an autosom...
1017  Tuberous sclerosis complex (TSC) is an autosom...
1018  Tuberous sclerosis complex (TSC) is an autosom...
1019  Tuberous sclerosis complex (TSC) is an autosom...
1020  Tuberous sclerosis complex (TSC) is an autosom...
1021  Tuberous sclerosis complex (TSC) is an autosom...
1022  Tuberous sclerosis complex (TSC) is an autosom...
1023  Tuberous sclerosis complex (TSC) is an autosom...
1024  Hamartin and tuberin are products of the tumor...
1025  Tuberous sclerosis complex (TSC) is an autosom...
1026  To report the clinical manifestations and func...
1027  To report the clinical manifestations and func...
1028  Tuberous sclerosis complex (TSC) is an autosom...
1029  Tuberous sclerosis (TSC) is an autosomal domin...
1030  Tuberous sclerosis complex (TSC) is an autosom...
1031  Tuberous sclerosis complex (TSC) is an autosom...
1032  To report the clinical manifestations and func...
1033  Tuberous sclerosis complex (TSC) is an autosom...
1034  Tuberous sclerosis (TSC) is an autosomal domin...
1035  Tuberous sclerosis complex (TSC) is an autosom...
1036  Abstract Large TSC gene rearrangements are not...
1037  Tuberous sclerosis complex (TSC) is an autosom...
1038  Tuberous sclerosis complex (TSC) is an autosom...
1039  Tuberous sclerosis complex (TSC) is an autosom...
1040  Tuberous sclerosis complex (TSC) is an autosom...
1041  Tuberous sclerosis complex (TSC) is an autosom...
1042  Tuberous sclerosis complex (TSC) is an autosom...
1043  Tuberous sclerosis complex (TSC) is an autosom...
1044  Tuberous sclerosis (TSC) is an autosomal domin...
1045  Tuberous sclerosis (TSC) is an autosomal domin...
1046  Tuberous sclerosis (TSC) is an autosomal domin...
1047  Tuberous sclerosis complex (TSC) is an autosom...
1048  Tuberous sclerosis (TSC) is an autosomal domin...
1049  The pathology associated with tuberous scleros...
1050  Tuberous sclerosis (TSC) is an autosomal domin...
1051  Tuberous sclerosis complex (TSC) is an autosom...
1052  Tuberous sclerosis complex (TSC) is an autosom...
1053  Tuberous sclerosis complex (TSC) is an autosom...
1054  Tuberous sclerosis complex (TSC) is an autosom...
1055  Tuberous sclerosis complex (TSC) is an autosom...
1056  Tuberous sclerosis complex (TSC) is an autosom...
1057  As a result of chromosome translocations, the ...
1058  Mesothelioma is a rare but very aggressive tum...
1059  Many soft tissue sarcomas have chromosomal tra...
1060   Fibroblast growth factors (FGFs) expressed in...
1061  Ewing’s sarcoma/PNET, a tumor of the bone and ...
1062  Sarcomas account for less than 10% of all huma...
1063   Approximately 75 % of extraskeletal myxoid ch...
1064  Many soft tissue sarcomas have chromosomal tra...
1065  Ewing’s sarcoma/PNET, a tumor of the bone and ...
1066  Many soft tissue sarcomas have chromosomal tra...
1067  Structural alterations of the Wilms' tumor loc...
1068  Diffuse Intrinsic Pontine Glioma (DIPG) is a f...
1069  Diffuse Intrinsic Pontine Glioma (DIPG) is a f...
1070  Diffuse Intrinsic Pontine Glioma (DIPG) is a f...
1071  Characterization of the prostate cancer transc...
1072  Characterization of the prostate cancer transc...
1073  The forkhead box (Fox) superfamily of transcri...
1074  Characterization of the prostate cancer transc...
1075  Characterization of the prostate cancer transc...
1076  Characterization of the prostate cancer transc...
1077  Forkhead box protein A1 (FOXA1) modulates the ...
1078  FoxA1 (FOXA1) is a pioneering transcription fa...
1079  ABSTRACT The p53 tumor suppressor gene is inac...
1080  ARID1A (BAF250A) promotes the formation of SWI...
1081  EZH2, the catalytic subunit of the PRC2 comple...
1082  EZH2, the catalytic subunit of the PRC2 comple...
1083  EZH2, the catalytic subunit of the PRC2 comple...
1084  EZH2, the catalytic subunit of the PRC2 comple...
1085  EZH2, the catalytic subunit of the PRC2 comple...
1086  Trimethylation of histone H3 on lysine 27 (H3K...
1087  EZH2 is a member of the polycomb group of gene...
1088  EZH2 is a member of the polycomb group of gene...
1089  9523192 Comparative genomic hybridization (CGH...
1090  Abstract Meningiomas are among the most freque...
1091  Urothelial carcinoma of the bladder is a commo...
1092  Urothelial carcinoma of the bladder is a commo...
1093  Langerhans cell histiocytosis (LCH) is now und...
1094  Passenger mutation rates are highly elevated i...
1095  Langerhans cell histiocytosis (LCH) is now und...
1096  Langerhans cell histiocytosis (LCH) is now und...
1097  The Wnt signaling pathway is essential for dev...
1098  Because only a small fraction of asbestos-expo...
1099  BRCA1 associated protein 1 (BAP1) is a nuclear...
1100  BAP1 is a tumor suppressor gene that is lost o...
1101  The deubiquitinating enzyme BRCA1-associated p...
1102  Because only a small fraction of asbestos-expo...
1103  BRCA1-associated protein 1 (BAP1) is a deubiqu...
1104  BRCA1 associated protein 1 (BAP1) is a nuclear...
1105  BAP1 (BRCA1-associated protein-1), a deubiquit...
1106  BRCA1 associated protein 1 (BAP1) is a nuclear...
1107   Multiple endocrine neoplasia type 1 (MEN1, OM...
1108  Fanconi anemia (FA) is an autosomal recessive ...
1109                                               null
1110   Abstract Fanconi anemia is characterized by c...
1111   Abstract Fanconi anemia (FA) is a genomic ins...
1112   Abstract Fanconi anemia (FA) is a genomic ins...
1113  Fanconi anemia (FA) is a genetic disease chara...
1114   Abstract Fanconi anemia (FA) is a genomic ins...
1115  Fanconi anemia (FA) is a recessively inherited...
1116   Abstract Fanconi anemia (FA) is a genomic ins...
1117  The Fanconi anemia (FA) group C gene product (...
1118  Non–small cell lung cancer (NSCLC) is a diffic...
1119  High-throughput sequencing promises to acceler...
1120  The Met receptor tyrosine kinase (RTK) regulat...
1121  Point mutations constitute a major mode of onc...
1122  The MET proto-oncogene product, which is the r...
1123  1. Introduction  The completion of the human g...
1124  During the last three decades, deregulated act...
1125  The assumption that genes encoding tyrosine ki...
1126  The Met receptor tyrosine kinase (RTK) regulat...
1127  The success of molecular targeted therapy in c...
1128  Point mutations constitute a major mode of onc...
1129  Non–small cell lung cancer (NSCLC) is a diffic...
1130  MET proto-oncogene, receptor tyrosine kinase g...
1131  Point mutations constitute a major mode of onc...
1132  Non–small cell lung cancer (NSCLC) is a diffic...
1133  BACKGROUND  The c-met protooncogene encodes th...
1134  Adenocarcinoma of the lung is the leading caus...
1135  INTRODUCTION  Tumor cell subpopulations emerge...
1136  Point mutations emerge as one of the rate-limi...
1137  MET proto-oncogene, receptor tyrosine kinase g...
1138  Non–small cell lung cancer (NSCLC) is a diffic...
1139  Summary During the past decade, the treatment ...
1140  Non–small cell lung cancer (NSCLC) is a diffic...
1141  Hereditary papifiary renal carcinoma (HPRC) is...
1142  Hereditary papillary renal carcinoma (HPRC) is...
1143  Studies of gene rearrangements and the consequ...
1144  Hereditary papillary renal carcinoma (HPRC) is...
1145  MET proto-oncogene, receptor tyrosine kinase g...
1146  Recurrent/metastatic head and neck cancer rema...
1147  To further understand the molecular distinctio...
1148  Non–small cell lung cancer (NSCLC) is a diffic...
1149  INTRODUCTION  Tumor cell subpopulations emerge...
1150  Major breast cancer predisposition genes, only...
1151  Heterozygous somatic mutations in the spliceos...
1152  Whole-exome sequencing studies have identified...
1153   Abstract Myelodysplastic syndromes (MDS) are ...
1154  Several studies indicated that the expression ...
1155  Epigenetic regulation lies at the heart of cel...
1156  MLL genes encode histone methyltransferases th...
1157   Abstract Monomethylation of histone H3 on Lys...
1158  Abstract. FAT1 [Homo sapiens FAT tumor suppres...
1159  Chromosome 4q35 is frequently lost in numerous...
1160  Chromosome 4q35 is frequently lost in numerous...
1161  introduction  Squamous-cell cancer of the head...
1162   Abstract Neuroblastomas are tumors of periphe...
1163  The human ATP-dependent SWItch/sucrose nonferm...
1164  Mutations in the PIK3CA gene, which encodes th...
1165  Large-scale sequencing efforts are uncovering ...
1166  Although several molecular markers predicting ...
1167  The PI3K/PTEN/AKT signaling pathway, a pathway...
1168  The p110α catalytic subunit (PIK3CA) is one of...
1169  Mutations in genes functioning in different pa...
1170  Class IA phosphoinositide 3-kinases (PI3Ks) tr...
1171  We previously reported four PIK3CA mutations i...
1172  Mutations in the PIK3CA gene, which encodes th...
1173  BRAF inhibitors elicit rapid anti-tumor respon...
1174   Introduction In 2004, Samuels et al. reported...
1175   Introduction In 2004, Samuels et al. reported...
1176   ABSTRACT Germline mutations in the BRCAJ tumo...
1177  Some clinical findings have suggested that sys...
1178  Purpose  The goal of this study was to compreh...
1179  Large-scale sequencing efforts are uncovering ...
1180  Fifteen rare cancer-derived mutants of PIK3CA,...
1181  BACKGROUND  Phosphatidylinositol-4,5-bisphosph...
1182  Fifteen rare cancer-derived mutants of PIK3CA,...
1183  The PI3K/PTEN/AKT signaling pathway, a pathway...
1184  The PI3K/PTEN/AKT signaling pathway, a pathway...
1185  The PI3K/PTEN/AKT signaling pathway, a pathway...
1186   Introduction In 2004, Samuels et al. reported...
1187  Activation of the phosphoinositide 3-kinase (P...
1188  Purpose  The goal of this study was to compreh...
1189  PIK3CA-related overgrowth spectrum (PROS) incl...
1190   ABSTRACT Germline mutations in the BRCAJ tumo...
1191  Many human cancers involve up-regulation of th...
1192   Introduction In 2004, Samuels et al. reported...
1193  The PI3K/PTEN/AKT signaling pathway, a pathway...
1194   Introduction In 2004, Samuels et al. reported...
1195  Activation of the phosphoinositide 3-kinase (P...
1196  Large-scale sequencing efforts are uncovering ...
1197  Advanced urothelial carcinoma (UC) of the blad...
1198  Ovarian cancer is the fifth-leading cause of c...
1199   Introduction In 2004, Samuels et al. reported...
1200   Introduction In 2004, Samuels et al. reported...
1201  The phosphatidylinositol 3-kinase (PI3K) pathw...
1202  Fifteen rare cancer-derived mutants of PIK3CA,...
1203  Large-scale sequencing efforts are uncovering ...
1204  The macrocephaly-capillary malformation syndro...
1205  The PIK3CA gene, coding for the catalytic subu...
1206  Many human cancers involve up-regulation of th...
1207  Fifteen rare cancer-derived mutants of PIK3CA,...
1208  Lung cancer is one of the most prevalent cance...
1209  Genomic findings underscore the heterogeneity ...
1210  Lung cancer is one of the most prevalent cance...
1211  The p110α catalytic subunit (PIK3CA) is one of...
1212   Introduction In 2004, Samuels et al. reported...
1213   Introduction In 2004, Samuels et al. reported...
1214   Introduction In 2004, Samuels et al. reported...
1215  PIK3CA, encoding the p110A catalytic subunit o...
1216   Introduction In 2004, Samuels et al. reported...
1217  The phosphatidylinositol 3-kinase (PI3K) pathw...
1218  Large-scale sequencing efforts are uncovering ...
1219  Fifteen rare cancer-derived mutants of PIK3CA,...
1220  Deregulation of the PI3K signaling pathway is ...
1221  The PIK3CA gene encoding the p110α subunit of ...
1222  Toward development of a precision medicine fra...
1223  Deregulation of the PI3K signaling pathway is ...
1224  Toward development of a precision medicine fra...
1225  Activation of the phosphoinositide 3-kinase (P...
1226  Activation of the PI3K pathway occurs commonly...
1227   Abstract The PI3-kinase pathway is commonly a...
1228  Deregulation of the PI3K signaling pathway is ...
1229  Activation of the PI3K pathway occurs commonly...
1230  Pim1, a serine/threonine kinase, is involved i...
1231  Pim1, a serine/threonine kinase, is involved i...
1232  Pim1, a serine/threonine kinase, is involved i...
1233  Pim-1 kinase, a serine/threonine protein kinas...
1234  Pim-1 kinase, a serine/threonine protein kinas...
1235  Pim-1 kinase, a serine/threonine protein kinas...
1236  Pim-1 kinase, a serine/threonine protein kinas...
1237  Pim1, a serine/threonine kinase, is involved i...
1238  Genetic mutations cause primary immunodeficien...
1239  The p110δ subunit of phosphoinositide 3-kinase...
1240  Genetic mutations cause primary immunodeficien...
1241  Conventional epithelioid hemangioendotheliomas...
1242  The development of array comparative genomic h...
1243  Ependymal tumors across age groups are current...
1244  Ependymal tumors across age groups are current...
1245   ABSTRACT Cancer-specific mutations in the iSH...
1246   ABSTRACT Cancer-specific mutations in the iSH...
1247  Class IA phosphatidylinositol 3-kinases (PI3K)...
1248  Previously characterized mutants of the p85α r...
1249   Abstract Bladder cancers commonly show geneti...
1250  The present study focused on the prognostic ro...
1251   ABSTRACT Cancer-specific mutations in the iSH...
1252   Abstract Bladder cancers commonly show geneti...
1253   Abstract Bladder cancers commonly show geneti...
1254   Abstract Bladder cancers commonly show geneti...
1255  Previously characterized mutants of the p85α r...
1256   SUMMARY Members of the mammalian phosphoinosi...
1257  Class IA phosphatidylinositol 3-kinases (PI3K)...
1258   ABSTRACT Cancer-specific mutations in the iSH...
1259   ABSTRACT Cancer-specific mutations in the iSH...
1260   ABSTRACT Cancer-specific mutations in the iSH...
1261  Class IA phosphatidylinositol 3-kinases (PI3K)...
1262   ABSTRACT Cancer-specific mutations in the iSH...
1263   Abstract Bladder cancers commonly show geneti...
1264   Abstract Bladder cancers commonly show geneti...
1265   Abstract PI3K is an important therapeutic tar...
1266   Abstract Bladder cancers commonly show geneti...
1267   ABSTRACT Cancer-specific mutations in the iSH...
1268   ABSTRACT Cancer-specific mutations in the iSH...
1269  Bilateral perisylvian polymicrogyria (BPP), th...
1270  We demonstrate that phosphatidylinositol 3-kin...
1271  Structural rearrangements of chromosome 10 are...
1272  We demonstrate that phosphatidylinositol 3-kin...
1273  We report an 8-year-old boy with a complex cer...
1274  We demonstrate that phosphatidylinositol 3-kin...
1275  We demonstrate that phosphatidylinositol 3-kin...
1276  We demonstrate that phosphatidylinositol 3-kin...
1277                                               null
1278  The three-dimensional structure of the complex...
1279  The treatment of metastatic colorectal cancer ...
1280  Most chemically induced rat mammary carcinomas...
1281   Activating mutations in v-Ha-ras Harvey rat s...
1282   Activating mutations in v-Ha-ras Harvey rat s...
1283  Background: In numerous biological events the ...
1284  The three-dimensional structure of the complex...
1285  The three-dimensional structure of the complex...
1286  Costello syndrome is a rare congenital disorde...
1287  BACKGROUND  Cutaneous squamous-cell carcinomas...
1288  Background: In numerous biological events the ...
1289  Mutations in RAS proteins occur widely in huma...
1290  We report a 10-year-old girl presenting with s...
1291  Cancer develops after the acquisition of a col...
1292  KRAS mutations occur in one third of human can...
1293  The three-dimensional structure of the complex...
1294  Several groups have shown that Noonan syndrome...
1295  The three-dimensional structure of the complex...
1296  Ras is a key signaling molecule in living cell...
1297   Cardio-facio-cutaneous (CFC) syndrome is char...
1298  KRAS mutations occur in one third of human can...
1299  Ras and Rapl proteins are related GTP-dependen...
1300  Mismatch-repair factors have a prominent role ...
1301   ABSTRACT: The hereditary colon and endometriu...
1302  Large-scale screening for germ-line mutations ...
1303  In hereditary nonpolyposis colorectal cancer (...
1304   ABSTRACT: The hereditary colon and endometriu...
1305  Mismatch-repair factors have a prominent role ...
1306  Hereditary non-polyposis colorectal cancer (HN...
1307  Mismatch-repair factors have a prominent role ...
1308  Numerous mismatch repair (MMR) gene variants h...
1309  Identification of a high-risk disease-causing ...
1310  Human colorectal cancer cell lines are used wi...
1311  Mismatch-repair factors have a prominent role ...
1312  Mismatch-repair factors have a prominent role ...
1313  Identification of a high-risk disease-causing ...
1314  Mismatch-repair factors have a prominent role ...
1315  Identification of a high-risk disease-causing ...
1316  In order to assess whether variations affectin...
1317  Mismatch-repair factors have a prominent role ...
1318  Germ-line mutations in the hMLH1 gene are the ...
1319  Identification of a high-risk disease-causing ...
1320  Identification of a high-risk disease-causing ...
1321  Mismatch-repair factors have a prominent role ...
1322  Mismatch-repair factors have a prominent role ...
1323   ABSTRACT DNA mismatch repair maintains genomi...
1324  Human colorectal cancer cell lines are used wi...
1325  Abstract We characterized four pancreatic carc...
1326  Identification of a high-risk disease-causing ...
1327  Cancers arise from the sequential acquisition ...
1328  Mismatch-repair factors have a prominent role ...
1329  Mismatch-repair factors have a prominent role ...
1330  Identification of a high-risk disease-causing ...
1331  Mismatch-repair factors have a prominent role ...
1332  Mismatch-repair factors have a prominent role ...
1333  Mismatch-repair factors have a prominent role ...
1334  Identification of a high-risk disease-causing ...
1335  The fibroblast growth factor receptor (FGFR) c...
1336  The fibroblast growth factor receptor (FGFR) c...
1337  Human chromosome 11q23 translocations disrupti...
1338  Epigenetic regulation lies at the heart of cel...
1339  Epigenetic regulation lies at the heart of cel...
1340  Cancer genome characterization efforts now pro...
1341  The protein kinase v-akt murine thymoma viral ...
1342  The protein kinase v-akt murine thymoma viral ...
1343  The protein kinase encoded by the Akt proto-on...
1344  The serine/threonine protein kinase encoded by...
1345  The protein kinase v-akt murine thymoma viral ...
1346  The protein kinase v-akt murine thymoma viral ...
1347  Cancer genome characterization efforts now pro...
1348  The protein kinase v-akt murine thymoma viral ...
1349  The phosphatidylinositol-3-kinase (PI3 kinase)...
1350  The protein kinase v-akt murine thymoma viral ...
1351  The protein kinase v-akt murine thymoma viral ...
1352  The serine–threonine kinase AKT regulates prol...
1353  The protein kinase v-akt murine thymoma viral ...
1354  The protein kinase v-akt murine thymoma viral ...
1355  The protein kinase v-akt murine thymoma viral ...
1356  The protein kinase v-akt murine thymoma viral ...
1357  The protein kinase v-akt murine thymoma viral ...
1358   Abstract Protein kinase B (Akt) kinases are c...
1359  The protein kinase v-akt murine thymoma viral ...
1360  The protein kinase v-akt murine thymoma viral ...
1361  The protein kinase v-akt murine thymoma viral ...
1362  The protein kinase v-akt murine thymoma viral ...
1363  The protein kinase v-akt murine thymoma viral ...
1364  The protein kinase v-akt murine thymoma viral ...
1365  The protein kinase v-akt murine thymoma viral ...
1366  The protein kinase v-akt murine thymoma viral ...
1367  Oestrogen-receptor-positive breast cancer exhi...
1368  The activating E17K mutations recently discove...
1369  The serine–threonine kinase AKT regulates prol...
1370  The serine–threonine kinase AKT regulates prol...
1371  The serine–threonine kinase AKT regulates prol...
1372  The activating E17K mutations recently discove...
1373  The serine–threonine kinase AKT regulates prol...
1374  High-grade serous ovarian cancer (HGSC) is the...
1375  The serine–threonine kinase AKT regulates prol...
1376  We previously demonstrated that the putative o...
1377  In response to extracellular stimuli, Akt kina...
1378  The activating E17K mutations recently discove...
1379  The FOP-fibroblast growth factor receptor 1 (F...
1380  Purpose: This study investigated whether mutat...
1381  The hallmark of the 8p12 stem cell myeloprolif...
1382  The 8p11 myeloproliferative syndrome is an agg...
1383  The genetic basis of morphological variation b...
1384  The fibroblast growth factor receptor (FGFR) c...
1385  null  Abstract Through a prospective clinical ...
1386   Abstract  The Notch and fibroblast growth fac...
1387   Abstract Through a prospective clinical seque...
1388  Introduction  Chronic myelogenous leukemia (CM...
1389   Abstract Through a prospective clinical seque...
1390  Papillary glioneuronal tumors (PGNTs) are rare...
1391  We report a patient with T-lymphoblastic leuke...
1392  Fibroblast growth-factor receptor 3 (FGFR3) be...
1393  Frequent genetic alterations discovered in FGF...
1394  Although activating mutations of FGFR3 are fre...
1395  Frequent genetic alterations discovered in FGF...
1396  Introduction Hypochondroplasia (MIM 146000) is...
1397  Frequent genetic alterations discovered in FGF...
1398   Abstract  Multiple myeloma is a genetically h...
1399  Frequent genetic alterations discovered in FGF...
1400  Frequent genetic alterations discovered in FGF...
1401  Frequent genetic alterations discovered in FGF...
1402  Introduction Hypochondroplasia (MIM 146000) is...
1403   Abstract  Various human skeletal disorders ar...
1404  Frequent genetic alterations discovered in FGF...
1405  Introduction Hypochondroplasia (MIM 146000) is...
1406  Fibroblast growth factor receptor 3 (FGFR3) is...
1407                                               null
1408  Frequent genetic alterations discovered in FGF...
1409  Frequent genetic alterations discovered in FGF...
1410  FGF receptor 3 (FGFR3) is activated by mutatio...
1411  Frequent genetic alterations discovered in FGF...
1412  Frequent genetic alterations discovered in FGF...
1413  Frequent genetic alterations discovered in FGF...
1414  Frequent genetic alterations discovered in FGF...
1415  Frequent genetic alterations discovered in FGF...
1416  Frequent genetic alterations discovered in FGF...
1417  The t(4;14) translocation occurs frequently in...
1418  Cancers arise owing to mutations in a subset o...
1419  Two mutations in FGFR3, G380R and G375C are kn...
1420  Frequent genetic alterations discovered in FGF...
1421  Frequent genetic alterations discovered in FGF...
1422  Although activating mutations of FGFR3 are fre...
1423  Although activating mutations of FGFR3 are fre...
1424  The A391E mutation in fibroblast growth factor...
1425  Introduction Hypochondroplasia (MIM 146000) is...
1426  Introduction Hypochondroplasia (MIM 146000) is...
1427   Abstract  Various human skeletal disorders ar...
1428  Frequent genetic alterations discovered in FGF...
1429  Fusion genes are chromosomal aberrations that ...
1430  Activating mutations in the fibroblast growth ...
1431  In the largest E3 ligase subfamily, Cul3 binds...
1432  In the largest E3 ligase subfamily, Cul3 binds...
1433  In the largest E3 ligase subfamily, Cul3 binds...
1434  In the largest E3 ligase subfamily, Cul3 binds...
1435  In the largest E3 ligase subfamily, Cul3 binds...
1436  In the largest E3 ligase subfamily, Cul3 binds...
1437  In the largest E3 ligase subfamily, Cul3 binds...
1438  In the largest E3 ligase subfamily, Cul3 binds...
1439  In the largest E3 ligase subfamily, Cul3 binds...
1440  In the largest E3 ligase subfamily, Cul3 binds...
1441  In the largest E3 ligase subfamily, Cul3 binds...
1442  In the largest E3 ligase subfamily, Cul3 binds...
1443  In the largest E3 ligase subfamily, Cul3 binds...
1444  In the largest E3 ligase subfamily, Cul3 binds...
1445  In the largest E3 ligase subfamily, Cul3 binds...
1446  In the largest E3 ligase subfamily, Cul3 binds...
1447  In the largest E3 ligase subfamily, Cul3 binds...
1448  In the largest E3 ligase subfamily, Cul3 binds...
1449  In the largest E3 ligase subfamily, Cul3 binds...
1450  The ERG gene is fused to TMPRSS2 in approximat...
1451  Introduction  Melanoma is the most lethal of a...
1452  Introduction  Melanoma is the most lethal of a...
1453  Craniosynostosis is a condition in which some ...
1454  Beare-Stevenson cutis gyrata syndrome (BSS) is...
1455  Activating mutations in the tyrosine kinase do...
1456  Intrahepatic cholangiocarcinoma (iCCA) is a fa...
1457  The discovery of oncogenic driver mutations an...
1458  Advanced cholangiocarcinoma continues to harbo...
1459  The discovery of oncogenic driver mutations an...
1460  Introduction  Melanoma is the most lethal of a...
1461  Introduction  Melanoma is the most lethal of a...
1462  It is known that FGFR2 gene variations confer ...
1463  We sought to identify fibroblast growth factor...
1464  Cholangiocarcinoma is an intractable cancer, w...
1465  Introduction  Melanoma is the most lethal of a...
1466  We sought to identify fibroblast growth factor...
1467  The fibroblast growth factor receptor (FGFR) c...
1468  Introduction  Melanoma is the most lethal of a...
1469  Multiple human skeletal and craniosynostosis d...
1470  Intrahepatic cholangiocarcinoma (iCCA) is a fa...
1471  We sought to identify fibroblast growth factor...
1472  Endometrial carcinoma is the most common gynec...
1473  Cholangiocarcinoma is an intractable cancer, w...
1474  Introduction  Melanoma is the most lethal of a...
1475  Activating mutations in the tyrosine kinase do...
1476  The purposes of this study were to find a nove...
1477  Introduction  Melanoma is the most lethal of a...
1478  We sought to identify fibroblast growth factor...
1479  Activating mutations in the tyrosine kinase do...
1480  Introduction  Melanoma is the most lethal of a...
1481  The discovery of oncogenic driver mutations an...
1482   Abstract Through a prospective clinical seque...
1483  The discovery of oncogenic driver mutations an...
1484  Fgf and Tgfβ are key regulators of bone develo...
1485  Oncogenic activation of tyrosine kinases is a ...
1486  We sought to identify fibroblast growth factor...
1487  The discovery of oncogenic driver mutations an...
1488  Signaling through FGF receptors, which constit...
1489  We sought to identify fibroblast growth factor...
1490  Retrospective studies have demonstrated that n...
1491   Abstract Through a prospective clinical seque...
1492  Introduction  Melanoma is the most lethal of a...
1493  Activating mutations in the tyrosine kinase do...
1494  Oncogenic activation of tyrosine kinases is a ...
1495  Oncogenic activation of tyrosine kinases is a ...
1496  Activating mutations in the tyrosine kinase do...
1497   Abstract Fibroblast growth factor receptor 2 ...
1498  We sought to identify fibroblast growth factor...
1499  Endometrial carcinoma is the most common gynec...
1500  Introduction  Melanoma is the most lethal of a...
1501  Rhabdomyosarcoma (RMS) is a childhood cancer o...
1502  Rhabdomyosarcoma (RMS) is a childhood cancer o...
1503  The 22 members of the fibroblast growth factor...
1504   Abstract Somatically acquired epigenetic chan...
1505   Abstract Somatically acquired epigenetic chan...
1506  In the era of personalized medicine, understan...
1507  ALK is involved in the onset of several tumors...
1508  In the era of personalized medicine, understan...
1509  Anaplastic lymphoma kinase (ALK) [1] is an imp...
1510  Nucleophosmin-anaplastic lymphoma kinase (NPM-...
1511  EML4–ALK fusions define a subset of lung cance...
1512  EML4–ALK fusions define a subset of lung cance...
1513  Introduction  Chromosomal translocations invol...
1514  In the era of personalized medicine, understan...
1515  In the era of personalized medicine, understan...
1516  The oncogenic property of anaplastic lymphoma ...
1517  In the era of personalized medicine, understan...
1518  In the era of personalized medicine, understan...
1519  In neuroblastoma, the ALK receptor tyrosine ki...
1520  Most anaplastic lymphoma kinase (ALK)–positive...
1521  In the era of personalized medicine, understan...
1522  The oncogenic property of anaplastic lymphoma ...
1523  In the era of personalized medicine, understan...
1524  The first-generation ALK tyrosine kinase inhib...
1525  Activated anaplastic lymphoma kinase (ALK) gen...
1526  Anaplastic lymphoma kinase (ALK) tyrosine kina...
1527  In the era of personalized medicine, understan...
1528  EML4–ALK fusions define a subset of lung cance...
1529  In the era of personalized medicine, understan...
1530  In the era of personalized medicine, understan...
1531  Most anaplastic lymphoma kinase (ALK)–positive...
1532  Thyroid cancer is a common endocrine malignanc...
1533  Introduction  Chromosomal translocations invol...
1534  In the era of personalized medicine, understan...
1535  In the era of personalized medicine, understan...
1536  In the era of personalized medicine, understan...
1537  In the era of personalized medicine, understan...
1538  Recently, the anaplastic lymphoma kinase (ALK)...
1539  In the era of personalized medicine, understan...
1540  Most anaplastic lymphoma kinase (ALK)–positive...
1541  In the era of personalized medicine, understan...
1542  In the era of personalized medicine, understan...
1543  In the era of personalized medicine, understan...
1544  The first-generation ALK tyrosine kinase inhib...
1545  In the era of personalized medicine, understan...
1546  We report the preclinical evaluation of PF-064...
1547  Patients with anaplastic lymphoma kinase (ALK)...
1548  In the era of personalized medicine, understan...
1549  In the era of personalized medicine, understan...
1550  Most anaplastic lymphoma kinase (ALK)–positive...
1551  Patients with anaplastic lymphoma kinase (ALK)...
1552  The dual ALK/MET inhibitor crizotinib was rece...
1553  In the era of personalized medicine, understan...
1554  In the era of personalized medicine, understan...
1555  In the era of personalized medicine, understan...
1556  In the era of personalized medicine, understan...
1557  In the era of personalized medicine, understan...
1558  In the era of personalized medicine, understan...
1559  In the era of personalized medicine, understan...
1560  The burgeoning field of anaplastic lymphoma ki...
1561  Anaplastic lymphoma kinase (ALK) [1] is an imp...
1562  In the era of personalized medicine, understan...
1563  The oncogenic property of anaplastic lymphoma ...
1564  In the era of personalized medicine, understan...
1565  In the era of personalized medicine, understan...
1566  In the era of personalized medicine, understan...
1567  EML4–ALK fusions define a subset of lung cance...
1568  Patients with anaplastic lymphoma kinase (ALK)...
1569  In the era of personalized medicine, understan...
1570  The oncogenic property of anaplastic lymphoma ...
1571  In the era of personalized medicine, understan...
1572  Various human cancers have ALK gene translocat...
1573  In the era of personalized medicine, understan...
1574  In the era of personalized medicine, understan...
1575  Pheochromocytomas (PCCs) are rare tumors that ...
1576  In Saccharomyces cerevisiae, homologous recomb...
1577  Mitochondrial complex II (succinate dehydrogen...
1578  Death rates from hepatocellular carcinoma (HCC...
1579  Introduction  Familial essential thrombocythem...
1580  Recently, a gain-of-function MPL mutation, MPL...
1581  The JAK2V617F allele has recently been identif...
1582  The interaction between thrombopoietin (THPO) ...
1583  HEREDITARY nonpolyposis colorectal cancer (HNP...
1584  Coactivator-associated arginine methyltransfer...
1585  Coactivator-associated arginine methyltransfer...
1586  Coactivator-associated arginine methyltransfer...
1587  orkhead box O (FoxO) transcription factors Fox...
1588  The von Hippel-Lindau tumor suppressor protein...
1589  Mutational hotspots indicate selective pressur...
1590  The von Hippel-Lindau tumor suppressor protein...
1591  The von Hippel-Lindau tumor suppressor protein...
1592  To understand the role of hypoxia-inducible fa...
1593  The von Hippel-Lindau tumor suppressor protein...
1594  We examined the biogenesis of the von Hippel-L...
1595  The autosomal dominantly inherited disorder vo...
1596  Missense mutation of VHL gene is frequently de...
1597  The eukaryotic chaperonin TRiC/CCT mediates fo...
1598  Mutations in the von Hippel–Lindau (VHL) gene ...
1599  The eukaryotic chaperonin TRiC/CCT mediates fo...
1600  Chuvash polycythemia (CP) is a rare congenital...
1601  The von Hippel-Lindau tumor suppressor protein...
1602  Missense mutation of VHL gene is frequently de...
1603  The eukaryotic chaperonin TRiC/CCT mediates fo...
1604  In von Hippel-Lindau (VHL) disease, germline m...
1605   Abstract  The von Hippel-Lindau (VHL) gene pr...
1606  The von Hippel-Lindau tumor suppressor protein...
1607  The eukaryotic chaperonin TRiC/CCT mediates fo...
1608  Mutations of von Hippel–Lindau disease (VHL) t...
1609  In von Hippel-Lindau (VHL) disease, germline m...
1610  The eukaryotic chaperonin TRiC/CCT mediates fo...
1611   Abstract  The von Hippel-Lindau (VHL) gene pr...
1612   Abstract  The von Hippel-Lindau (VHL) gene pr...
1613  The case of a 40-year-old woman with severe ed...
1614  Chuvash polycythemia (CP) is a rare congenital...
1615  The von Hippel-Lindau tumor suppressor protein...
1616  The eukaryotic chaperonin TRiC/CCT mediates fo...
1617  The eukaryotic chaperonin TRiC/CCT mediates fo...
1618   Abstract  The von Hippel-Lindau (VHL) gene pr...
1619   Abstract  The von Hippel-Lindau (VHL) gene pr...
1620  Background: von Hippel-Lindau (VHL) disease is...
1621  Von Hippel-Lindau (VHL) disease is a hereditar...
1622  The von Hippel-Lindau tumor suppressor protein...
1623   Abstract  The von Hippel-Lindau (VHL) gene pr...
1624  In von Hippel-Lindau (VHL) disease, germline m...
1625  Mutational hotspots indicate selective pressur...
1626  The von Hippel-Lindau tumor suppressor protein...
1627  The autosomal dominantly inherited disorder vo...
1628  Mutations of von Hippel–Lindau disease (VHL) t...
1629  MAP2K4 encodes a dual-specificity kinase (mito...
1630  The systematic characterization of somatic mut...
1631  The systematic characterization of somatic mut...
1632  MAP2K4 encodes a dual-specificity kinase (mito...
1633  MAP2K4 encodes a dual-specificity kinase (mito...
1634  The systematic characterization of somatic mut...
1635  MAP2K4 encodes a dual-specificity kinase (mito...
1636  The systematic characterization of somatic mut...
1637  MAP2K4 encodes a dual-specificity kinase (mito...
1638   ABSTRACT As an approach to identify human onc...
1639                                               null
1640  Internal tandem duplications of the FMS-like t...
1641  Mutations of receptor tyrosine kinases are imp...
1642  The t(8;21) and inv(16)/t(16;16) rearrangement...
1643  An internal tandem duplication (ITD) of the FL...
1644  Mutations of receptor tyrosine kinases are imp...
1645  In acute myeloid leukemia (AML), two clusters ...
1646  Mutations in the juxtamembrane and kinase doma...
1647  Mutations in the juxtamembrane and kinase doma...
1648  In acute myeloid leukemia (AML), two clusters ...
1649  In acute myeloid leukemia (AML), two clusters ...
1650  Mutations in the juxtamembrane and kinase doma...
1651  About 30% of patients with acute myeloid leuke...
1652  FLT3 is constitutively activated by internal t...
1653  The t(8;21) and inv(16)/t(16;16) rearrangement...
1654  An internal tandem duplication (ITD) of the FL...
1655  An internal tandem duplication (ITD) of the FL...
1656  An internal tandem duplication (ITD) of the FL...
1657  The FLT3 receptor tyrosine kinase is constitut...
1658  An internal tandem duplication (ITD) of the FL...
1659  Mutations in the receptor tyrosine kinase FLT3...
1660  Mutations in the juxtamembrane and kinase doma...
1661  Mutations in the juxtamembrane and kinase doma...
1662  Tyrosine kinase domain mutations are a common ...
1663  Tyrosine kinase domain mutations are a common ...
1664  FMS-like tyrosine kinase 3 (FLT3) inhibitors h...
1665  Mutations in the juxtamembrane and kinase doma...
1666  Mutations in the juxtamembrane and kinase doma...
1667  In acute myeloid leukemia (AML), two clusters ...
1668  Mutations in the juxtamembrane and kinase doma...
1669  Mutations in the juxtamembrane and kinase doma...
1670  Mutations of receptor tyrosine kinases are imp...
1671  Fms-like tyrosine kinase 3 (FLT3) receptor mut...
1672  Mutations of receptor tyrosine kinases are imp...
1673  Mutations in the juxtamembrane and kinase doma...
1674  An internal tandem duplication (ITD) of the FL...
1675  An internal tandem duplication (ITD) of the FL...
1676  An internal tandem duplication (ITD) of the FL...
1677  An internal tandem duplication (ITD) of the FL...
1678  In acute myeloid leukemia (AML), two clusters ...
1679  An internal tandem duplication (ITD) of the FL...
1680  Introduction  FLT3, a class 3 receptor tyrosin...
1681  Mutations in the juxtamembrane and kinase doma...
1682  An internal tandem duplication (ITD) of the FL...
1683  Mutations of receptor tyrosine kinases are imp...
1684  An internal tandem duplication (ITD) of the FL...
1685  About 30% of patients with acute myeloid leuke...
1686  A considerable number of patients with metasta...
1687  An internal tandem duplication (ITD) of the FL...
1688  Early signal relay steps upon ligand binding t...
1689  Identification of a high-risk disease-causing ...
1690  Identification of a high-risk disease-causing ...
1691  The DNA mismatch repair (MMR) protein dimer Mu...
1692  Purpose The clinical consequences of PMS2 germ...
1693  Hereditary nonpolyposis colorectal cancer (HNP...
1694   ABSTRACT DNA mismatch repair maintains genomi...
1695  Identification of a high-risk disease-causing ...
1696  Identification of a high-risk disease-causing ...
1697  Background Inherited mutations in DNA mismatch...
1698  Identification of a high-risk disease-causing ...
1699  Lynch syndrome (LS; also known as hereditary n...
1700  Identification of a high-risk disease-causing ...
1701  Lynch syndrome (LS) is a common cancer predisp...
1702  The MutL  heterodimer formed by mismatch repai...
1703  Identification of a high-risk disease-causing ...
1704  Identification of a high-risk disease-causing ...
1705  Mutations in the spliceosomal genes SRSF2, U2A...
1706  Acute lymphoblastic leukemia (ALL) is a neopla...
1707  PPM1D (WIP1) negatively regulates by dephospho...
1708  Tumors with somatic mutations in the proofread...
1709  Tumors with somatic mutations in the proofread...
1710  Tumors with somatic mutations in the proofread...
1711  Tumors with somatic mutations in the proofread...
1712  Tumors with somatic mutations in the proofread...
1713   Abstract Genomic sequences encoding the 3′ ex...
1714  Tumors with somatic mutations in the proofread...
1715  Tumors with somatic mutations in the proofread...
1716  Tumors with somatic mutations in the proofread...
1717  Many individuals with multiple or large colore...
1718  Here we report the discovery of recurrent muta...
1719  Here we report the discovery of recurrent muta...
1720  Here we report the discovery of recurrent muta...
1721  Here we report the discovery of recurrent muta...
1722  Lymphatic malformations (LM) are characterized...
1723  Classical familial adenomatous polyposis (FAP)...
1724  We identified the APC N1026S variant of unknow...
1725  Society's investment in basic biological re-  ...
1726  1. Introduction Familial adenomatous polyposis...
1727  Familial adenomatous polyposis, an autosomal-d...
1728  The mammalian target of rapamycin (mTOR) kinas...
1729  Identification of a high-risk disease-causing ...
1730  Identification of a high-risk disease-causing ...
1731   Abstract In December 1997, the National Cance...
1732  Identification of a high-risk disease-causing ...
1733  Identification of a high-risk disease-causing ...
1734  In order to assess whether variations affectin...
1735  Identification of a high-risk disease-causing ...
1736  Identification of a high-risk disease-causing ...
1737  Hereditary predisposition to colorectal cancer...
1738   Background & Aims: Inherited deleterious muta...
1739  Identification of a high-risk disease-causing ...
1740  Identification of a high-risk disease-causing ...
1741  Identification of a high-risk disease-causing ...
1742  Identification of a high-risk disease-causing ...
1743  The cancer predisposition in most HNPCC famili...
1744  Identification of a high-risk disease-causing ...
1745  Hereditary non-polyposis colon cancer (HNPCC),...
1746  Identification of a high-risk disease-causing ...
1747   Summary Hereditary nonpolyposis colorectal ca...
1748  Identification of a high-risk disease-causing ...
1749   ABSTRACT: Lynch syndrome is one of the most c...
1750  Introduction Somatic mutations in human cytoso...
1751  Mutations in metabolic enzymes, including isoc...
1752  Introduction Somatic mutations in human cytoso...
1753  Mutations in the genes for isocitrate dehydrog...
1754  Current genomic and biochemical analysis revea...
1755  Monoallelic point mutations in cytosolic isoci...
1756  Current genomic and biochemical analysis revea...
1757  Cancer genome characterization efforts now pro...
1758  Introduction Somatic mutations in human cytoso...
1759  Introduction Somatic mutations in human cytoso...
1760  Introduction Somatic mutations in human cytoso...
1761  Introduction Somatic mutations in human cytoso...
1762  Introduction Somatic mutations in human cytoso...
1763  Introduction Somatic mutations in human cytoso...
1764  Introduction Somatic mutations in human cytoso...
1765  Cancer genome characterization efforts now pro...
1766  Cellular metabolism and cancer Discussions on ...
1767  Monoallelic point mutations in cytosolic isoci...
1768  Heterozygous mutations in either the R132 resi...
1769  The somatic mutations in cytosolic isocitrate ...
1770  Cancer genome characterization efforts now pro...
1771  The common participation of oncogenic KRAS pro...
1772  Massively parallel sequencing enables the sequ...
1773  An exome-sequencing study of families with mul...
1774  An exome-sequencing study of families with mul...
1775  Relapsed acute lymphoblastic leukaemia (ALL) i...
1776  Relapsed acute lymphoblastic leukaemia (ALL) i...
1777  Relapsed acute lymphoblastic leukaemia (ALL) i...
1778  Relapsed acute lymphoblastic leukaemia (ALL) i...
1779  Relapsed acute lymphoblastic leukaemia (ALL) i...
1780  Acetylation of nucleosomal histones is a major...
1781  Relapsed acute lymphoblastic leukaemia (ALL) i...
1782  The cortisol/cortisone-responsive AR (ARccr) h...
1783  Androgen receptor (AR) mutations are associate...
1784  Androgen receptor (AR) mutations are associate...
1785  To study a new sequence variant at the beginni...
1786  Androgen receptor (AR) splice variants lacking...
1787  Androgen receptor (AR) mutations are associate...
1788  An androgen receptor (AR) gene mutation identi...
1789  An androgen receptor (AR) gene mutation identi...
1790  Androgen receptor (AR) mutations are associate...
1791  Most prostate cancers (PCs) become resistant t...
1792  Most prostate cancers (PCs) become resistant t...
1793  An androgen receptor (AR) gene mutation identi...
1794  Overexpression of amplified genes is often ass...
1795  Androgen receptor (AR) mutations are associate...
1796  Despite the impressive clinical activity of th...
1797  Androgen receptor (AR) mutations are associate...
1798  Androgen receptor (AR) mutations are associate...
1799  Despite the impressive clinical activity of th...
1800  Androgen receptor (AR) mutations are associate...
1801  Androgen receptor (AR) splice variants lacking...
1802  Intrahepatic cholangiocarcinoma (iCCA) is a fa...
1803  Targeted cancer therapies often induce “outlie...
1804  Targeted cancer therapies often induce “outlie...
1805  The extracellular signal-regulated kinase (ERK...
1806  The extracellular signal-regulated kinase (ERK...
1807  Targeted cancer therapies often induce “outlie...
1808  Intrahepatic cholangiocarcinoma (iCCA) is a fa...
1809  Rho family small GTPases serve as molecular sw...
1810  Angioimmunoblastic T cell lymphoma (AITL) is a...
1811  Diffuse-type gastric carcinoma (DGC) is charac...
1812  AITL is a common subtype of T cell lymphoma, a...
1813  Mutational hotspots indicate selective pressur...
1814  Gastric cancer is a heterogeneous disease with...
1815   Abstract  Burkitt lymphoma (BL) is the most f...
1816   Abstract  Adhesion of tumor cells to host cel...
1817  Rho family small GTPases serve as molecular sw...
1818  The RhoA GTPase regulates diverse cellular pro...
1819  Mutational hotspots indicate selective pressur...
1820   Abstract  Adhesion of tumor cells to host cel...
1821  Mutational hotspots indicate selective pressur...
1822  Proteins of the Rho family of small GTPases ar...
1823  Mutational hotspots indicate selective pressur...
1824  Mutational hotspots indicate selective pressur...
1825  Mutational hotspots indicate selective pressur...
1826  Estrogen receptors (ERs) are normally expresse...
1827  A recent genome-wide sequencing analysis of al...
1828  A recent genome-wide sequencing analysis of al...
1829  Protein Phosphatase 2A (PP2A) plays an essenti...
1830  Protein Phosphatase 2A (PP2A) plays an essenti...
1831  A recent genome-wide sequencing analysis of al...
1832  Protein Phosphatase 2A (PP2A) plays an essenti...
1833  A recent genome-wide sequencing analysis of al...
1834  Protein Phosphatase 2A (PP2A) plays an essenti...
1835  Protein Phosphatase 2A (PP2A) plays an essenti...
1836  Protein Phosphatase 2A (PP2A) plays an essenti...
1837  A recent genome-wide sequencing analysis of al...
1838  Protein Phosphatase 2A (PP2A) plays an essenti...
1839  Histone methyltransferases (HMTs) are importan...
1840  Acute leukemia characterized by chromosomal re...
1841  The yeast Set2 histone methyltransferase is a ...
1842  The insulin-like growth factor I receptor (IGF...
1843  The insulin-like growth factor I receptor (IGF...
1844  Background: IGF-I receptor (IGF1R) plays an es...
1845  Mutations in the PPP6C catalytic subunit of pr...
1846  Mutations in the PPP6C catalytic subunit of pr...
1847  Mutations in the PPP6C catalytic subunit of pr...
1848  Mutations in the PPP6C catalytic subunit of pr...
1849  Introduction  CTCF was originally identified a...
1850  Introduction  CTCF was originally identified a...
1851  Gastric cancer is a leading cause of cancer de...
1852  Introduction  CTCF was originally identified a...
1853  It is estimated that more than 50 000 cases of...
1854  The karyotypic chaos exhibited by human epithe...
1855  Introduction  Mammalian target of rapamycin (m...
1856  Genes encoding components of the PI3K-Akt-mTOR...
1857  Genes encoding components of the PI3K-Akt-mTOR...
1858  Genes encoding components of the PI3K-Akt-mTOR...
1859  Renal cell carcinomas with unclassified histol...
1860  Genes encoding components of the PI3K-Akt-mTOR...
1861  Genes encoding components of the PI3K-Akt-mTOR...
1862  Genes encoding components of the PI3K-Akt-mTOR...
1863  Intratumor heterogeneity may foster tumor evol...
1864  Mammalian target of rapamycin (mTOR) is a seri...
1865  Genes encoding components of the PI3K-Akt-mTOR...
1866  Genes encoding components of the PI3K-Akt-mTOR...
1867  Understanding the genetic mechanisms of sensit...
1868  Genomic studies have linked mTORC1 pathway–act...
1869  Genes encoding components of the PI3K-Akt-mTOR...
1870  Genes encoding components of the PI3K-Akt-mTOR...
1871  Introduction  Mammalian target of rapamycin (m...
1872  Genes encoding components of the PI3K-Akt-mTOR...
1873  Genes encoding components of the PI3K-Akt-mTOR...
1874  Genes encoding components of the PI3K-Akt-mTOR...
1875  Genes encoding components of the PI3K-Akt-mTOR...
1876  Genes encoding components of the PI3K-Akt-mTOR...
1877  Genomic studies have linked mTORC1 pathway–act...
1878  Mammalian target of rapamycin (mTOR) is a seri...
1879  Genes encoding components of the PI3K-Akt-mTOR...
1880  Genes encoding components of the PI3K-Akt-mTOR...
1881  The MCF-7 breast cancer cell line was exposed ...
1882  Genes encoding components of the PI3K-Akt-mTOR...
1883  Introduction  In recent years, a better unders...
1884  The MCF-7 breast cancer cell line was exposed ...
1885  Genes encoding components of the PI3K-Akt-mTOR...
1886  Genes encoding components of the PI3K-Akt-mTOR...
1887  The MCF-7 breast cancer cell line was exposed ...
1888  Genes encoding components of the PI3K-Akt-mTOR...
1889  Mammalian target of rapamycin (mTOR) is a seri...
1890  Genes encoding components of the PI3K-Akt-mTOR...
1891  Mammalian target of rapamycin (mTOR) is a seri...
1892  Understanding the genetic mechanisms of sensit...
1893  Genes encoding components of the PI3K-Akt-mTOR...
1894  Genes encoding components of the PI3K-Akt-mTOR...
1895  Genes encoding components of the PI3K-Akt-mTOR...
1896  Mammalian target of rapamycin (mTOR) is a seri...
1897  Genes encoding components of the PI3K-Akt-mTOR...
1898  Genes encoding components of the PI3K-Akt-mTOR...
1899  Genes encoding components of the PI3K-Akt-mTOR...
1900  The TET proteins are 2-oxoglutarate- and Fe(II...
1901  MLL translocations in adult B-cell precursor (...
1902  TET2 is a close relative of TET1, an enzyme th...
1903  Small cell carcinoma of the ovary, hypercalcem...
1904  Rhabdoid tumors of early infancy are highly ag...
1905  Topoisomerase 1 (TOP1) is an enzyme that relie...
1906  Small cell carcinoma of the ovary of hypercalc...
1907  Recent exon sequencing studies of human tumors...
1908  Small cell carcinoma of the ovary, hypercalcem...
1909  SNF5/INI1 is a component of the ATP-dependent ...
1910  Inactivation of the switch/sucrose nonfermenta...
1911  The transcriptional network of the androgen re...
1912  De novo disruptions of the neural transcriptio...
1913  Inappropriate Hedgehog (Hh) signaling has been...
1914  Introduction Uncontrolled activation of the He...
1915   Basal activities of adenylate cyclase and gua...
1916  Introduction Uncontrolled activation of the He...
1917  The Hedgehog (Hh) signaling pathway is inappro...
1918  The Hedgehog (Hh) signaling pathway is inappro...
1919  Introduction Uncontrolled activation of the He...
1920  Introduction Uncontrolled activation of the He...
1921  Introduction Uncontrolled activation of the He...
1922  Introduction Basal cell carcinoma (BCC) is the...
1923  Introduction Uncontrolled activation of the He...
1924  Introduction Basal cell carcinoma (BCC) is the...
1925   Basal activities of adenylate cyclase and gua...
1926   Basal activities of adenylate cyclase and gua...
1927  Introduction Uncontrolled activation of the He...
1928  Major progress has been made in recent years i...
1929   Basal activities of adenylate cyclase and gua...
1930  Basal cell carcinomas (BCCs) are locally invas...
1931  Introduction Basal cell carcinoma (BCC) is the...
1932  Hedgehog (Hh) pathway activation promotes tumo...
1933  Inappropriate Hedgehog (Hh) signaling has been...
1934  Three new BENTA patients sharing the same nove...
1935  The regulated activation of NF-κB by antigen r...
1936  Left ventricular (LV) remodeling is a signific...
1937  Self-tolerance and immunity are actively acqui...
1938  Self-tolerance and immunity are actively acqui...
1939  Self-tolerance and immunity are actively acqui...
1940  Self-tolerance and immunity are actively acqui...
1941  The regulated activation of NF-κB by antigen r...
1942  Left ventricular (LV) remodeling is a signific...
1943  Self-tolerance and immunity are actively acqui...
1944  Diffuse large B cell lymphoma (DLBCL) is a com...
1945  Mycosis fungoides and Sézary syndrome are prim...
1946  The MEF2B gene encodes a transcriptional activ...
1947  The MEF2B gene encodes a transcriptional activ...
1948  The MEF2B gene encodes a transcriptional activ...
1949  The MEF2B gene encodes a transcriptional activ...
1950  The MEF2B gene encodes a transcriptional activ...
1951  Myocyte enhancer factor 2B (MEF2B) is a transc...
1952  Rheumatoid arthritis (RA) and juvenile rheumat...
1953  Over 1,000 reports have been published during ...
1954  Ataxia telangiectasia (A-T) is a rare autosoma...
1955  The genetic characterization of chronic lympho...
1956  Ataxia telangiectasia (A-T) is a rare autosoma...
1957  Ataxia telangiectasia (A-T) is a rare autosoma...
1958  The involvement of ATM gene and specifically, ...
1959   Abstract Nucleoporins (NUPs) are essential co...
1960   Abstract Nucleoporins (NUPs) are essential co...
1961   Abstract Nucleoporins (NUPs) are essential co...
1962  Cervical cancer is responsible for 10–15% of c...
1963  Introduction  Epidermal growth factor receptor...
1964  beta-catenin is a multifunctional protein invo...
1965  We screened 75 primary hepatocellular carcinom...
1966  We screened 75 primary hepatocellular carcinom...
1967  We screened 75 primary hepatocellular carcinom...
1968  We screened 75 primary hepatocellular carcinom...
1969  Gain-of-function mutations in exon 3 of β-cate...
1970  We screened 75 primary hepatocellular carcinom...
1971  β-Catenin-mediated signaling can be constituti...
1972  We screened 75 primary hepatocellular carcinom...
1973  We screened 75 primary hepatocellular carcinom...
1974  We screened 75 primary hepatocellular carcinom...
1975  Limb-bud and heart (LBH) is a novel key transc...
1976  We screened 75 primary hepatocellular carcinom...
1977  Gain-of-function mutations in exon 3 of β-cate...
1978  We screened 75 primary hepatocellular carcinom...
1979  We screened 75 primary hepatocellular carcinom...
1980  We screened 75 primary hepatocellular carcinom...
1981  beta-catenin is a multifunctional protein invo...
1982  We screened 75 primary hepatocellular carcinom...
1983  Gain-of-function mutations in exon 3 of β-cate...
1984  We screened 75 primary hepatocellular carcinom...
1985  To understand the nature and roles of mutated ...
1986  We screened 75 primary hepatocellular carcinom...
1987  We screened 75 primary hepatocellular carcinom...
1988  We screened 75 primary hepatocellular carcinom...
1989  Histiocytic neoplasms are clonal, hematopoieti...
1990  Genetic alterations that activate the mitogen-...
1991  Many clinical cases of acquired resistance to ...
1992  How genomic heterogeneity associated with acqu...
1993   Abstract The scirrhous subtype of gastric can...
1994  Utilizing a genetic screen in the yeast Saccha...
1995   Abstract The scirrhous subtype of gastric can...
1996  Recent results from clinical trials with the B...
1997  t Although targeting the Ras/Raf/MEK pathway r...
1998  No effective systemic therapy exists for patie...
1999  Histiocytic neoplasms are clonal, hematopoieti...
2000  Genetic alterations that activate the mitogen-...
2001  Mitogen-activated protein kinases (MAPKs) are ...
2002  MEK1 and MEK2 are related protein kinases that...
2003  The MAPK/ERK pathway (RAS–RAF–MEK–ERK pathway)...
2004  Histiocytic neoplasms are clonal, hematopoieti...
2005  Recent results from clinical trials with the B...
2006  Histiocytic neoplasms are clonal, hematopoieti...
2007  The ERK signalling pathway is activated by an ...
2008  Histiocytic neoplasms are clonal, hematopoieti...
2009  Among gynecologic cancers, ovarian cancer is t...
2010  The MAPK/ERK pathway (RAS–RAF–MEK–ERK pathway)...
2011  Utilizing a genetic screen in the yeast Saccha...
2012  Genetic alterations that activate the mitogen-...
2013  Genetic alterations that activate the mitogen-...
2014  Genetic alterations that activate the mitogen-...
2015  Background: MEK1 mutations in melanoma can con...
2016  Most patients with BRAFV600 metastatic melanom...
2017  Genetic alterations that activate the mitogen-...
2018  Histiocytic neoplasms are clonal, hematopoieti...
2019  Mitogen-activated protein kinases (MAPKs) are ...
2020  Most patients with BRAFV600 metastatic melanom...
2021   Abstract The scirrhous subtype of gastric can...
2022  Utilizing a genetic screen in the yeast Saccha...
2023  The MAPK/ERK pathway (RAS–RAF–MEK–ERK pathway)...
2024  Histiocytic neoplasms are clonal, hematopoieti...
2025  Histiocytic neoplasms are clonal, hematopoieti...
2026  We performed exome sequencing to detect somati...
2027  Most patients with BRAFV600 metastatic melanom...
2028  Histiocytic neoplasms are clonal, hematopoieti...
2029  angerhans cell histiocytosis (LCH) is characte...
2030  Mitogen-activated protein kinases (MAPKs) are ...
2031  The MAPK/ERK pathway (RAS–RAF–MEK–ERK pathway)...
2032   Abstract Cardio-facio-cutaneous (CFC) syndrom...
2033  Cardio-facio-cutaneous (CFC) and Costello synd...
2034  Cardio-facio-cutaneous (CFC) and Costello synd...
2035  The Ras/MAPK pathway is critical for human dev...
2036  Most patients with BRAFV600 metastatic melanom...
2037  Cardiofaciocutaneous (CFC) syndrome is a rar e...
2038  Most patients with BRAFV600 metastatic melanom...
2039   Abstract Cardio-facio-cutaneous (CFC) syndrom...
2040   Abstract Cardio-facio-cutaneous (CFC) syndrom...
2041  We performed exome sequencing to detect somati...
2042  Most patients with BRAFV600 metastatic melanom...
2043  The myelodysplastic syndromes are a group of h...
2044  Signaling mediated by IL-7 and IL-7R is essent...
2045  The identification of biologically significant...
2046  The identification of biologically significant...
2047   Noonan syndrome, the most common single-gene ...
2048  The identification of biologically significant...
2049  Noonan syndrome (NS), estimated to affect 1 ou...
2050  The identification of biologically significant...
2051   ABSTRACT The cytoplasmic Myc protein (c-Myc) ...
2052   Abstract Medulloblastoma, a small blue cell m...
2053  c-myc, N-myc and L-myc are the three members o...
2054  Evasion of apoptosis is critical in Myc-induce...
2055  Burkitt's lymphoma is a highly aggressive B-ce...
2056  c-myc, N-myc and L-myc are the three members o...
2057   Abstract  Transformation from follicular lymp...
2058  A powerful way to discover key genes playing c...
2059  Neuroblastoma is a tumour derived from primiti...
2060  Neuroblastoma is a malignancy of the developin...
2061  In humans, mutations in SOX9 result in a skele...
2062  In humans, mutations in SOX9 result in a skele...
2063  Sox9 is a transcription factor that is critica...
2064  SOX9 inactivation is frequent in colorectal ca...
2065  In humans, mutations in SOX9 result in a skele...
2066  In humans, mutations in SOX9 result in a skele...
2067  In humans, mutations in SOX9 result in a skele...
2068  TET proteins oxidize 5-methylcytosine (5mC) on...
2069  The TET proteins are 2-oxoglutarate- and Fe(II...
2070  TET proteins oxidize 5-methylcytosine (5mC) on...
2071  TET proteins oxidize 5-methylcytosine (5mC) on...
2072  TET proteins oxidize 5-methylcytosine (5mC) on...
2073  TET proteins oxidize 5-methylcytosine (5mC) on...
2074  TET proteins oxidize 5-methylcytosine (5mC) on...
2075  TET proteins oxidize 5-methylcytosine (5mC) on...
2076  TET proteins oxidize 5-methylcytosine (5mC) on...
2077  TET proteins oxidize 5-methylcytosine (5mC) on...
2078  TET proteins oxidize 5-methylcytosine (5mC) on...
2079  TET proteins oxidize 5-methylcytosine (5mC) on...
2080  TET proteins oxidize 5-methylcytosine (5mC) on...
2081  TET proteins oxidize 5-methylcytosine (5mC) on...
2082  Myeloid differentiation 88 (MyD88) is the key ...
2083  MYD88L265P has recently been discovered as an ...
2084  MYD88 L265P is a somatic mutation that has bee...
2085  Argonaute (Ago) proteins mediate silencing of ...
2086  Argonaute (Ago) proteins mediate silencing of ...
2087  Argonaute (Ago) proteins mediate silencing of ...
2088  Argonaute (Ago) 2 is the catalytic engine of m...
2089  Argonaute (Ago) proteins mediate silencing of ...
2090  Epigenetic regulation lies at the heart of cel...
2091  Although a small decrease in survival and incr...
2092  The proteins encoded by ATRX and DAXX particip...
2093  The proteins encoded by ATRX and DAXX particip...
2094  Introduction  BRCA1 and BRCA2 mutations are fo...
2095  Introduction  BRCA1 and BRCA2 mutations are fo...
2096  Introduction  BRCA1 and BRCA2 mutations are fo...
2097  Introduction  BRCA1 and BRCA2 mutations are fo...
2098  Introduction  BRCA1 and BRCA2 mutations are fo...
2099  Introduction  BRCA1 and BRCA2 mutations are fo...
2100  Introduction  BRCA1 and BRCA2 mutations are fo...
2101  Introduction  BRCA1 and BRCA2 mutations are fo...
2102  Introduction  BRCA1 and BRCA2 mutations are fo...
2103  Introduction  BRCA1 and BRCA2 mutations are fo...
2104  ntroduction p53 mutations are common in lung c...
2105  Rhabdomyosarcoma (RMS), a cancer of skeletal m...
2106  We report that diffuse large B-cell lymphoma (...
2107  Hodgkin lymphoma (HL) is characterized by a mi...
2108  Hodgkin lymphoma (HL) is characterized by a mi...
2109  We report that diffuse large B-cell lymphoma (...
2110  How the genomic landscape of a tumor shapes an...
2111  How the genomic landscape of a tumor shapes an...
2112  The discovery of Rous sarcoma virus (RSV) led ...
2113  The non-receptor tyrosine kinase c-Src, hereaf...
2114  Clinicians continue to better define the overl...
2115  Almost all neuroblastoma tumors express excess...
2116  Hypoparathyroidism, sensorineural deafness and...
2117  Our genetic material is continuously challenge...
2118  The activities of cyclin D-dependent kinases s...
2119  The activities of cyclin D-dependent kinases s...
2120  Leukaemic mantle cell lymphoma is considered t...
2121  A series of our previous studies demonstrated ...
2122  The activities of cyclin D-dependent kinases s...
2123   Abstract A gene expression signature of tumor...
2124  Although cyclin D1 is overexpressed in a signi...
2125  The activities of cyclin D-dependent kinases s...
2126  This is a comprehensive whole-genome/whole-exo...
2127  Although cyclin D1 is overexpressed in a signi...
2128  The activities of cyclin D-dependent kinases s...
2129  Although cyclin D1 is overexpressed in a signi...
2130  The activities of cyclin D-dependent kinases s...
2131  Abstract: Double-hit lymphoma (DHL) has been d...
2132  NRF2 is a transcription factor that mediates s...
2133  Nuclear factor erythroid-2 related factor 2 (N...
2134  NRF2 is a transcription factor that mediates s...
2135  Oxidative and electrophilic stresses are sense...
2136  Oxidative and electrophilic stresses are sense...
2137  NRF2 is a transcription factor that mediates s...
2138  NRF2 is a transcription factor that mediates s...
2139  Oxidative and electrophilic stresses are sense...
2140  NRF2 is a transcription factor that mediates s...
2141  NRF2 is a transcription factor that mediates s...
2142  Nuclear factor erythroid-2 related factor 2 (N...
2143  NRF2 is a transcription factor that mediates s...
2144  NRF2 is a transcription factor that mediates s...
2145  Protein ubiquitylation is a post-translational...
2146  Basal cell carcinoma (BCC) is the most common ...
2147   Abstract Hedgehog (Hh) signaling is largely s...
2148  The PTEN (phosphatase and tensin homolog) phos...
2149  The PTEN (phosphatase and tensin homolog) phos...
2150  Germline mutations in the phosphatase PTEN are...
2151  The tumor suppressor gene PTEN is frequently m...
2152  The PTEN (phosphatase and tensin homolog) phos...
2153  The PTEN (phosphatase and tensin homolog) phos...
2154  The tumor suppressor gene PTEN is frequently m...
2155  The tumor suppressor gene PTEN is frequently m...
2156  The PTEN (phosphatase and tensin homolog) phos...
2157  The PTEN (phosphatase and tensin homolog) phos...
2158  The tumor suppressor gene PTEN is frequently m...
2159  Phosphatase and tensin homolog deleted on chro...
2160  The tumor suppressor gene PTEN is frequently m...
2161  The PTEN (phosphatase and tensin homolog) phos...
2162  Germline mutations in the phosphatase PTEN are...
2163  The PTEN (phosphatase and tensin homolog) phos...
2164  Diffuse large B-cell lymphoma (DLBCL) represen...
2165  Melanoma is the most lethal form of skin cance...
2166  The tumor suppressor gene PTEN is frequently m...
2167  The PTEN (phosphatase and tensin homolog) phos...
2168  The tumor suppressor gene phosphatase and tens...
2169  The PTEN (phosphatase and tensin homolog) phos...
2170  The tumor suppressor gene PTEN is frequently m...
2171  We screened mutations of two major tumor suppr...
2172  The PTEN (phosphatase and tensin homolog) phos...
2173  The tumor suppressor gene PTEN is frequently m...
2174  The tumor suppressor gene PTEN is frequently m...
2175  Diffuse large B-cell lymphoma (DLBCL) represen...
2176  Phosphatase and tensin homolog (PTEN)-inactiva...
2177  The tumor suppressor gene PTEN is frequently m...
2178   ABSTRACT To look for a direct role of ultravi...
2179  We screened mutations of two major tumor suppr...
2180  Germline mutations in the phosphatase PTEN are...
2181  The PTEN (phosphatase and tensin homolog) phos...
2182   ABSTRACT To look for a direct role of ultravi...
2183  The PTEN (phosphatase and tensin homolog) phos...
2184  The PTEN (phosphatase and tensin homolog) phos...
2185  The PTEN (phosphatase and tensin homolog) phos...
2186  The PTEN (phosphatase and tensin homolog) phos...
2187  The PTEN (phosphatase and tensin homolog) phos...
2188  The PTEN (phosphatase and tensin homolog) phos...
2189  The PTEN (phosphatase and tensin homolog) phos...
2190  The tumor suppressor gene PTEN is frequently m...
2191  Germline intragenic mutations in PTEN are asso...
2192  The PTEN (phosphatase and tensin homolog) phos...
2193  The PTEN (phosphatase and tensin homolog) phos...
2194  The PTEN (phosphatase and tensin homolog) phos...
2195  The PTEN (phosphatase and tensin homolog) phos...
2196   ABSTRACT To look for a direct role of ultravi...
2197  The tumor suppressor gene phosphatase and tens...
2198  The tumour suppressor gene PTEN , which maps t...
2199  The PTEN (phosphatase and tensin homolog) phos...
2200  The tumor suppressor gene PTEN is frequently m...
2201  The PTEN (phosphatase and tensin homolog) phos...
2202  The PTEN (phosphatase and tensin homolog) phos...
2203  The PTEN (phosphatase and tensin homolog) phos...
2204  Somatic and germline mutations in PTEN (phosph...
2205  Germline mutations in PTEN have been described...
2206  The PTEN (phosphatase and tensin homolog) phos...
2207  We screened mutations of two major tumor suppr...
2208  The PTEN (phosphatase and tensin homolog) phos...
2209  The PTEN (phosphatase and tensin homolog) phos...
2210  The PTEN (phosphatase and tensin homolog) phos...
2211  The PTEN (phosphatase and tensin homolog) phos...
2212  The tumor suppressor gene PTEN is frequently m...
2213  The PTEN (phosphatase and tensin homolog) phos...
2214  The PTEN (phosphatase and tensin homolog) phos...
2215  The PTEN (phosphatase and tensin homolog) phos...
2216  The PTEN (phosphatase and tensin homolog) phos...
2217  The PTEN (phosphatase and tensin homolog) phos...
2218  The tumour suppressor gene PTEN , which maps t...
2219  The tumor suppressor gene phosphatase and tens...
2220  The PTEN (phosphatase and tensin homolog) phos...
2221  The tumour suppressor gene PTEN , which maps t...
2222  The PTEN (phosphatase and tensin homolog) phos...
2223  The tumor suppressor gene PTEN is frequently m...
2224  The PTEN (phosphatase and tensin homolog) phos...
2225  The PTEN (phosphatase and tensin homolog) phos...
2226  The tumor suppressor gene PTEN is frequently m...
2227   Abstract  The signaling pathways involving cl...
2228  The PTEN (phosphatase and tensin homolog) phos...
2229  The tumor suppressor gene phosphatase and tens...
2230  The tumour suppressor gene PTEN , which maps t...
2231  The PTEN (phosphatase and tensin homolog) phos...
2232  The PTEN (phosphatase and tensin homolog) phos...
2233  The PTEN (phosphatase and tensin homolog) phos...
2234  The tumor suppressor gene PTEN is frequently m...
2235  Phosphatase and tensin homolog (PTEN)-inactiva...
2236  The tumor suppressor gene PTEN is frequently m...
2237  Germline mutations in the phosphatase PTEN are...
2238  The PTEN (phosphatase and tensin homolog) phos...
2239  Germline mutations in the phosphatase PTEN are...
2240  The tumor suppressor gene PTEN is frequently m...
2241  The tumor suppressor gene PTEN is frequently m...
2242  The tumour suppressor gene PTEN , which maps t...
2243  Somatic and germline mutations in PTEN (phosph...
2244  The PTEN (phosphatase and tensin homolog) phos...
2245  The PTEN (phosphatase and tensin homolog) phos...
2246  The PTEN (phosphatase and tensin homolog) phos...
2247  The PTEN (phosphatase and tensin homolog) phos...
2248  Germline mutations in the phosphatase PTEN are...
2249  The tumor suppressor gene phosphatase and tens...
2250  PTEN is a recently identified tumor suppressor...
2251  The tumor suppressor gene PTEN is frequently m...
2252  The tumor suppressor gene PTEN is frequently m...
2253  Somatic and germline mutations in PTEN (phosph...
2254  The PTEN (phosphatase and tensin homolog) phos...
2255  The PTEN (phosphatase and tensin homolog) phos...
2256  The PTEN (phosphatase and tensin homolog) phos...
2257  The tumor suppressor gene PTEN is frequently m...
2258  The tumor suppressor gene PTEN is frequently m...
2259   ABSTRACT To look for a direct role of ultravi...
2260  The PTEN (phosphatase and tensin homolog) phos...
2261   ABSTRACT To look for a direct role of ultravi...
2262  The PTEN (phosphatase and tensin homolog) phos...
2263  The PTEN (phosphatase and tensin homolog) phos...
2264  The tumor suppressor gene PTEN is frequently m...
2265  The PTEN (phosphatase and tensin homolog) phos...
2266  The PTEN (phosphatase and tensin homolog) phos...
2267  The PTEN (phosphatase and tensin homolog) phos...
2268  The tumor suppressor gene PTEN is frequently m...
2269  The PTEN (phosphatase and tensin homolog) phos...
2270  The PTEN (phosphatase and tensin homolog) phos...
2271  The PTEN (phosphatase and tensin homolog) phos...
2272  Metastasis associated protein 1 (MTA1) is a co...
2273  A broad spectrum of mutations in PTEN, encodin...
2274  The majority of acute promyelocytic leukemia (...
2275  Endometrial stromal sarcomas (ESS) are genetic...
2276  BCOR is a component of a variant Polycomb grou...
2277  The dysregulation of proper transcriptional co...
2278  he identification of subtype-specific transloc...
2279  The evolutionarily conserved Wnt/β-catenin sig...
2280  Oligodendroglioma is characterized by unique c...
2281  Oligodendroglioma is characterized by unique c...
2282  Oligodendroglioma is characterized by unique c...
2283  Primitive round cell sarcomas of childhood and...
2284  Primitive round cell sarcomas of childhood and...
2285  Although the gastrointestinal (GI) tract posse...
2286  Large granular lymphocyte (LGL) leukemia is a ...
2287  Lymphomas arising from NK or gd-T cells are ve...
2288  Lymphomas arising from NK or gd-T cells are ve...
2289  Abstract BACKGROUND' 'T-cell large granular ly...
2290  Lymphomas arising from NK or gd-T cells are ve...
2291  Autosomal dominant deficiency of signal transd...
2292  Autosomal dominant deficiency of signal transd...
2293  Autosomal dominant deficiency of signal transd...
2294  The 8p11-12 chromosome region is one of the re...
2295  Highlights  ► Disruption of BLIMP1 by inactiva...
2296  Highlights  ► Disruption of BLIMP1 by inactiva...
2297  Highlights  ► Disruption of BLIMP1 by inactiva...
2298   PRDM1/BLIMP-1, a master regulator of plasma-c...
2299  Highlights  ► Disruption of BLIMP1 by inactiva...
2300  Pediatric acute lymphoblastic leukemia (ALL) i...
2301  Activating mutations in JAK1 and JAK2 have bee...
2302  Regulatory T (T reg) cells have a major role i...
2303  Recent work has highlighted roles for JAK (Jan...
2304  T-cell acute lymphoblastic leukemia (T-ALL) is...
2305  The comprehensive genetic alterations underlyi...
2306  Activating mutations in JAK1 and JAK2 have bee...
2307  Recent work has highlighted roles for JAK (Jan...
2308  Summary Hepatocellular adenomas (HCA) are beni...
2309  Regulatory T (T reg) cells have a major role i...
2310  Activating mutations in JAK1 have been reporte...
2311  Mutations in PTK genes usually result in GOF m...
2312  A systematic characterization of the genetic a...
2313  Recent work has highlighted roles for JAK (Jan...
2314  Recent work has highlighted roles for JAK (Jan...
2315  Activating mutations in JAK1 and JAK2 have bee...
2316  Hepatocellular carcinoma (HCC) is one of the m...
2317  T-cell acute lymphoblastic leukemia (T-ALL) is...
2318  Polycythemia vera (PV), a myeloproliferative n...
2319   Abstract The JAK2 V617F mutation present in o...
2320  Myeloproliferative neoplasms (MPNs) are a grou...
2321  Myeloproliferative neoplasms (MPNs) are a grou...
2322  Introduction  The fusion protein PAX5-JAK2 has...
2323  The genetics of classical Hodgkin lymphoma (cH...
2324  Myeloproliferative neoplasms (MPNs) are a grou...
2325  Myeloproliferative neoplasms (MPNs) are a grou...
2326  Many myeloproliferative disorders (MPDs) are d...
2327  Janus kinase 2 (Jak2) is a cytoplasmic tyrosin...
2328  Myeloproliferative neoplasms (MPNs) are a grou...
2329  2. This mutation resulted in a myeloproliferat...
2330  Myeloproliferative neoplasms (MPNs) are a grou...
2331  2. This mutation resulted in a myeloproliferat...
2332  Philadelphia chromosome–like acute lymphoblast...
2333  Myeloproliferative neoplasms (MPNs) are a grou...
2334  Myeloproliferative neoplasms (MPNs) are a grou...
2335  Philadelphia chromosome–like acute lymphoblast...
2336  Myeloproliferative neoplasms (MPNs) are a grou...
2337  Myeloproliferative neoplasms (MPNs) are a grou...
2338  Myeloproliferative neoplasms (MPNs) are a grou...
2339   Abstract The JAK2 V617F mutation present in o...
2340  Children with Down's syndrome have a greatly i...
2341  Myeloproliferative neoplasms (MPNs) are a grou...
2342  Janus kinase 2 (JAK2) is an important mediator...
2343  Classical Hodgkin lymphoma (cHL) and mediastin...
2344  Myeloproliferative neoplasms (MPNs) are a grou...
2345  2. This mutation resulted in a myeloproliferat...
2346  Children with Down's syndrome have a greatly i...
2347  Myeloproliferative neoplasms (MPNs) are a grou...
2348  Chromosomal translocations resulting in altern...
2349  Children with Down's syndrome have a greatly i...
2350  Philadelphia chromosome–like acute lymphoblast...
2351  Genetic and biochemical studies in lower eukar...
2352  Linkage analysis and haplotype mapping in inte...
2353  Aurora-2 is a key member of a closely related ...
2354  Peutz-Jeghers syndrome (PJS) is an autosomal d...
2355  Peutz–Jeghers syndrome (PJS) is an autosomal d...
2356  Germline mutations in LKB1 have been reported ...
2357  Peutz-Jeghers syndrome (PJS) is an autosomal d...
2358   Abstract Germline mutations of the LKB1 gene ...
2359  Serine/threonine kinase 11 (STK11), better kno...
2360  Peutz-Jeghers syndrome (PJS) is an autosomal d...
2361  Peutz-Jeghers syndrome (PJS) is a rare, autoso...
2362  Peutz–Jeghers syndrome (PJS) is a rare heredit...
2363  The His-x-Asp (HxD) motif is one of the most c...
2364  To investigate whether genetic alteration of t...
2365  Peutz-Jeghers syndrome (PJS) is an autosomal d...
2366   Abstract Germline mutations of the LKB1 gene ...
2367  Genomic amplification of c-Jun and its upstrea...
2368  PTPN11, which encodes tyrosine phosphatase Shp...
2369  Noonan syndrome (NS) is characterized by short...
2370  Noonan syndrome (NS) is characterized by short...
2371  Protein-tyrosine phosphatases (PTPs) have key ...
2372  Protein-tyrosine phosphatases (PTPs) have key ...
2373  Noonan syndrome (NS) is characterized by short...
2374  Noonan syndrome (NS) is characterized by short...
2375  Noonan syndrome (NS) is characterized by short...
2376  The Src homology 2 (SH2) domain-containing pro...
2377  Noonan syndrome (NS) is characterized by short...
2378  Diverse cellular processes are regulated by ty...
2379  Tightly regulated cellular signaling is critic...
2380  Noonan syndrome (NS) is characterized by short...
2381  SHP2, encoded by the PTPN11 gene, is a protein...
2382  Protein-tyrosine phosphatases (PTPs) have key ...
2383  Noonan syndrome (NS) is characterized by short...
2384  The RASopathies are a relatively common group ...
2385   Abstract Shp2, an ubiquitously expressed prot...
2386  Noonan syndrome (NS) is characterized by short...
2387  Noonan syndrome is a developmental disorder wi...
2388  The Src homology 2 (SH2) domain-containing pro...
2389  Noonan syndrome (NS) is characterized by short...
2390  Noonan syndrome (NS) is characterized by short...
2391  Noonan syndrome (NS) is characterized by short...
2392  Protein-tyrosine phosphatases (PTPs) have key ...
2393  Germline mutations in PTPN11, the gene encodin...
2394  Ras (p21'as) interacts directly with the catal...
2395   Purpose: To analyze the spectrum and frequenc...
2396  Ras (p21'as) interacts directly with the catal...
2397  Ras (p21'as) interacts directly with the catal...
2398  Ras (p21'as) interacts directly with the catal...
2399  Ras (p21'as) interacts directly with the catal...
2400  Ras (p21'as) interacts directly with the catal...
2401   RasGAPs supply a catalytic residue, termed th...
2402  Ras (p21'as) interacts directly with the catal...
2403  Ras (p21'as) interacts directly with the catal...
2404  Cancer therapy has arguably entered a transfor...
2405  Ras (p21'as) interacts directly with the catal...
2406  Ras (p21'as) interacts directly with the catal...
2407  Ras (p21'as) interacts directly with the catal...
2408  Germline heterozygous alterations of the tumor...
2409  Ras (p21'as) interacts directly with the catal...
2410  Objective  It has been four years since the di...
2411  Recently, mutation of the FOXL2 gene has been ...
2412  Tyrosine phosphorylation plays a critical role...
2413  An additional tumor suppressor gene on chromos...
2414  Tyrosine phosphorylation plays a critical role...
2415  Tyrosine phosphorylation plays a critical role...
2416  Tyrosine phosphorylation plays a critical role...
2417   Abstract  The BRCA1 gene from individuals at ...
2418  Mutations in BRCA1 and BRCA2 account for the m...
2419  Germline mutations of the breast cancer 1 (BRC...
2420  Genetic screening of the breast and ovarian ca...
2421  BRCA1 and BRCA2 mutations are estimated to be ...
2422   Abstract  The BRCA1 gene from individuals at ...
2423  Genetic screening of the breast and ovarian ca...
2424   Abstract  The BRCA1 gene from individuals at ...
2425  Germline mutations of the breast cancer 1 (BRC...
2426  There have been few published analyses of the ...
2427  Germline mutations of the breast cancer 1 (BRC...
2428  Germline mutations of the breast cancer 1 (BRC...
2429  Mutations in BRCA1 and BRCA2 account for the m...
2430  Germline mutations of the breast cancer 1 (BRC...
2431  Mutations in BRCA1 and BRCA2 account for the m...
2432   Abstract  The BRCA1 gene from individuals at ...
2433  Germline mutations of the breast cancer 1 (BRC...
2434   Abstract  The BRCA1 gene from individuals at ...
2435  Germ line inactivating mutations in BRCA1 conf...
2436  Genetic screening of the breast and ovarian ca...
2437  Germline mutations of the breast cancer 1 (BRC...
2438  Genetic screening of the breast and ovarian ca...
2439  BRCA1 and BRCA2 mutations are estimated to be ...
2440  Genetic screening of the breast and ovarian ca...
2441   Abstract  The BRCA1 gene from individuals at ...
2442   Abstract  The BRCA1 gene from individuals at ...
2443   Abstract  The BRCA1 gene from individuals at ...
2444  Germline mutations of the breast cancer 1 (BRC...
2445  Mutations in BRCA1 and BRCA2 account for the m...
2446  Mutations in BRCA1 and BRCA2 account for the m...
2447  Mutations in BRCA1 and BRCA2 account for the m...
2448  There have been few published analyses of the ...
2449  Genetic screening of the breast and ovarian ca...
2450  Germline mutations of the breast cancer 1 (BRC...
2451  ABSTRACT: The BRCA1 tumor suppressor gene is f...
2452  There have been few published analyses of the ...
2453  Germline mutations of the breast cancer 1 (BRC...
2454  There have been few published analyses of the ...
2455   Abstract  The BRCA1 gene from individuals at ...
2456  BRCA1 is inactivated by gene mutations in >50%...
2457  Mutations in BRCA1 and BRCA2 account for the m...
2458  There have been few published analyses of the ...
2459   Abstract  The BRCA1 gene from individuals at ...
2460  Mutations in BRCA1 and BRCA2 account for the m...
2461  Germline mutations of the breast cancer 1 (BRC...
2462  Genetic screening of the breast and ovarian ca...
2463  ABSTRACT Germline mutations that inactivate th...
2464  Mutations in BRCA1 and BRCA2 account for the m...
2465  Mutations in BRCA1 and BRCA2 account for the m...
2466  Mutations in BRCA1 and BRCA2 account for the m...
2467  BRCA1 is a tumour suppressor with pleiotropic ...
2468  Mutations in BRCA1 and BRCA2 account for the m...
2469  Missense substitutions of uncertain clinical s...
2470  Genetic screening of the breast and ovarian ca...
2471  Mutations in BRCA1 and BRCA2 account for the m...
2472  Mutations in BRCA1 and BRCA2 account for the m...
2473  Mutations in BRCA1 and BRCA2 account for the m...
2474  Germline mutation analysis of BRCA1 gene has d...
2475   Abstract  The BRCA1 gene from individuals at ...
2476  ABSTRACT Germline mutations that inactivate th...
2477  BRCA1 is inactivated by gene mutations in >50%...
2478   Abstract  The BRCA1 gene from individuals at ...
2479  BRCA1 is inactivated by gene mutations in >50%...
2480  Mutations in BRCA1 and BRCA2 account for the m...
2481  Mutations in BRCA1 and BRCA2 account for the m...
2482   Abstract  The BRCA1 gene from individuals at ...
2483  Mutations in BRCA1 and BRCA2 account for the m...
2484   Abstract  The BRCA1 gene from individuals at ...
2485  ABSTRACT Germline mutations that inactivate th...
2486  Genetic screening of the breast and ovarian ca...
2487  Mutations in BRCA1 and BRCA2 account for the m...
2488  Mutations in BRCA1 and BRCA2 account for the m...
2489   Abstract  The BRCA1 gene from individuals at ...
2490  ABSTRACT Germline mutations that inactivate th...
2491   Abstract  The BRCA1 gene from individuals at ...
2492   Abstract  The BRCA1 gene from individuals at ...
2493  ABSTRACT: The BRCA1 tumor suppressor gene is f...
2494  Genetic screening of the breast and ovarian ca...
2495  Genetic screening of the breast and ovarian ca...
2496  Genetic screening of the breast and ovarian ca...
2497   Abstract  The BRCA1 gene from individuals at ...
2498  A significant proportion of inherited breast c...
2499  Missense substitutions of uncertain clinical s...
2500  Mutations in BRCA1 and BRCA2 account for the m...
2501   Abstract  The BRCA1 gene from individuals at ...
2502  Genetic screening of the breast and ovarian ca...
2503  Mutations in BRCA1 and BRCA2 account for the m...
2504   Identification of protein-protein interaction...
2505  Mutations in BRCA1 and BRCA2 account for the m...
2506   Abstract  The BRCA1 gene from individuals at ...
2507  There have been few published analyses of the ...
2508  Triple Negative Breast Cancers (TNBC) represen...
2509  Mutations in BRCA1 and BRCA2 account for the m...
2510   Abstract  The BRCA1 gene from individuals at ...
2511   Abstract  The BRCA1 gene from individuals at ...
2512   Abstract Germline inactivating mutations in B...
2513  A large number of missense mutations have been...
2514  Germline mutations of the breast cancer 1 (BRC...
2515  Germline mutations of the breast cancer 1 (BRC...
2516  Mutations in BRCA1 and BRCA2 account for the m...
2517  Germline mutations of the breast cancer 1 (BRC...
2518   Abstract  The BRCA1 gene from individuals at ...
2519  Mutations in BRCA1 and BRCA2 account for the m...
2520  Missense substitutions of uncertain clinical s...
2521  Germline mutations of the breast cancer 1 (BRC...
2522  Genetic screening of the breast and ovarian ca...
2523  Genetic screening of the breast and ovarian ca...
2524  Genetic screening of the breast and ovarian ca...
2525   Abstract  The BRCA1 gene from individuals at ...
2526   Abstract  The BRCA1 gene from individuals at ...
2527  BRCA1 is a tumour suppressor with pleiotropic ...
2528  ABSTRACT: The BRCA1 tumor suppressor gene is f...
2529  BRCA1 is inactivated by gene mutations in >50%...
2530   Abstract  The BRCA1 gene from individuals at ...
2531  Mutations in BRCA1 and BRCA2 account for the m...
2532  Genetic screening of the breast and ovarian ca...
2533  Genetic screening of the breast and ovarian ca...
2534  There have been few published analyses of the ...
2535  Mutations in BRCA1 and BRCA2 account for the m...
2536  Mutations in BRCA1 and BRCA2 account for the m...
2537  There have been few published analyses of the ...
2538  Genetic screening of the breast and ovarian ca...
2539  Mutations in BRCA1 and BRCA2 account for the m...
2540  Germline mutations of the breast cancer 1 (BRC...
2541   Abstract  The BRCA1 gene from individuals at ...
2542   Abstract  The BRCA1 gene from individuals at ...
2543  There have been few published analyses of the ...
2544  ABSTRACT Germline mutations that inactivate th...
2545  ABSTRACT Germline mutations that inactivate th...
2546  Mutations in BRCA1 and BRCA2 account for the m...
2547   Abstract  The BRCA1 gene from individuals at ...
2548  ABSTRACT Germline mutations that inactivate th...
2549  Genetic screening of the breast and ovarian ca...
2550  Germline mutations of the breast cancer 1 (BRC...
2551  Mutations in BRCA1 and BRCA2 account for the m...
2552  Genetic screening of the breast and ovarian ca...
2553   Abstract  The BRCA1 gene from individuals at ...
2554   Abstract Germline inactivating mutations in B...
2555   Abstract  The BRCA1 gene from individuals at ...
2556   Abstract  The BRCA1 gene from individuals at ...
2557   Abstract  The BRCA1 gene from individuals at ...
2558  ABSTRACT Germline mutations that inactivate th...
2559  There have been few published analyses of the ...
2560  Mutations in BRCA1 and BRCA2 account for the m...
2561  Mutations in BRCA1 and BRCA2 account for the m...
2562   Abstract Germline mutations in the tumor supp...
2563  Genetic screening of the breast and ovarian ca...
2564   Abstract  The BRCA1 gene from individuals at ...
2565  Genetic screening of the breast and ovarian ca...
2566  Genetic screening of the breast and ovarian ca...
2567   Abstract  The BRCA1 gene from individuals at ...
2568   Abstract  The BRCA1 gene from individuals at ...
2569   Abstract  The BRCA1 gene from individuals at ...
2570  ABSTRACT Germline mutations that inactivate th...
2571  Mutations in BRCA1 and BRCA2 account for the m...
2572  Germline mutations of the breast cancer 1 (BRC...
2573   Abstract  The BRCA1 gene from individuals at ...
2574   Abstract  The BRCA1 gene from individuals at ...
2575  Germline-inactivating mutations of BRCA1 resul...
2576  Mutations in BRCA1 and BRCA2 account for the m...
2577  Genetic screening of the breast and ovarian ca...
2578  Genetic screening of the breast and ovarian ca...
2579  Genetic screening of the breast and ovarian ca...
2580  There have been few published analyses of the ...
2581  Mutations in BRCA1 and BRCA2 account for the m...
2582   Abstract  The BRCA1 gene from individuals at ...
2583   Abstract  The BRCA1 gene from individuals at ...
2584   Abstract  The BRCA1 gene from individuals at ...
2585  Genetic screening of the breast and ovarian ca...
2586  BRCA1 is a tumour suppressor with pleiotropic ...
2587  Mutations in BRCA1 and BRCA2 account for the m...
2588  Mutations in BRCA1 and BRCA2 account for the m...
2589   Abstract  The BRCA1 gene from individuals at ...
2590  Germline mutations of the breast cancer 1 (BRC...
2591  Mutations in BRCA1 and BRCA2 account for the m...
2592  Genetic screening of the breast and ovarian ca...
2593  Germline mutations of the breast cancer 1 (BRC...
2594  Germline mutations of the breast cancer 1 (BRC...
2595   Abstract  The BRCA1 gene from individuals at ...
2596   Abstract  The BRCA1 gene from individuals at ...
2597  Germline mutations of the breast cancer 1 (BRC...
2598   Abstract  The BRCA1 gene from individuals at ...
2599   Abstract  The BRCA1 gene from individuals at ...
2600  ABSTRACT Germline mutations that inactivate th...
2601  Mutations in BRCA1 and BRCA2 account for the m...
2602  Mutations in BRCA1 and BRCA2 account for the m...
2603  Mutations in BRCA1 and BRCA2 account for the m...
2604  Mutations in BRCA1 and BRCA2 account for the m...
2605   Abstract  The BRCA1 gene from individuals at ...
2606  Germline mutations of the breast cancer 1 (BRC...
2607   Abstract  The BRCA1 gene from individuals at ...
2608   Abstract Germline inactivating mutations in B...
2609  Germline mutations of the breast cancer 1 (BRC...
2610   Abstract  The BRCA1 gene from individuals at ...
2611  ABSTRACT Germline mutations that inactivate th...
2612  Mutations in BRCA1 and BRCA2 account for the m...
2613  ABSTRACT Germline mutations that inactivate th...
2614  A large number of missense mutations have been...
2615  BRCA1 accumulates in nuclear foci during S-pha...
2616   Abstract  The BRCA1 gene from individuals at ...
2617  ABSTRACT Germline mutations that inactivate th...
2618   Abstract  The BRCA1 gene from individuals at ...
2619  ABSTRACT Germline mutations that inactivate th...
2620  Mutations in BRCA1 and BRCA2 account for the m...
2621   Abstract  The BRCA1 gene from individuals at ...
2622   Abstract  The BRCA1 gene from individuals at ...
2623  Mutations in BRCA1 and BRCA2 account for the m...
2624   Abstract  The BRCA1 gene from individuals at ...
2625  Mutations in BRCA1 and BRCA2 account for the m...
2626   Abstract  The BRCA1 gene from individuals at ...
2627  ABSTRACT: The BRCA1 tumor suppressor gene is f...
2628  Mutations in BRCA1 and BRCA2 account for the m...
2629  Missense substitutions of uncertain clinical s...
2630  ABSTRACT Germline mutations that inactivate th...
2631   Abstract  The BRCA1 gene from individuals at ...
2632  There have been few published analyses of the ...
2633  Germline mutations of the breast cancer 1 (BRC...
2634   Abstract Germline inactivating mutations in B...
2635   Abstract  The BRCA1 gene from individuals at ...
2636   Summary An account of familial aggregation in...
2637   Abstract  The BRCA1 gene from individuals at ...
2638  Genetic screening of the breast and ovarian ca...
2639  ABSTRACT Germline mutations that inactivate th...
2640   Abstract  The BRCA1 gene from individuals at ...
2641  Germ line inactivating mutations in BRCA1 conf...
2642   Abstract  The BRCA1 gene from individuals at ...
2643   Abstract Germline mutations that inactivate B...
2644  There have been few published analyses of the ...
2645  ABSTRACT: The BRCA1 tumor suppressor gene is f...
2646  ABSTRACT Germline mutations that inactivate th...
2647  Mutations in BRCA1 and BRCA2 account for the m...
2648  There have been few published analyses of the ...
2649  Missense substitutions of uncertain clinical s...
2650   ABSTRACT Mutations in BRCA1 account for 45% o...
2651  Mutations in BRCA1 and BRCA2 account for the m...
2652  ABSTRACT Germline mutations that inactivate th...
2653   Abstract  The BRCA1 gene from individuals at ...
2654  There have been few published analyses of the ...
2655  Mutations in BRCA1 and BRCA2 account for the m...
2656  Genetic screening of the breast and ovarian ca...
2657   Abstract  The BRCA1 gene from individuals at ...
2658  Germline mutations of the breast cancer 1 (BRC...
2659  Genetic screening of the breast and ovarian ca...
2660  Mutations in BRCA1 and BRCA2 account for the m...
2661   Abstract Germline mutations that inactivate B...
2662  Mutations in BRCA1 and BRCA2 account for the m...
2663  Germ line inactivating mutations in BRCA1 conf...
2664   Abstract  The BRCA1 gene from individuals at ...
2665  Germline mutations of the breast cancer 1 (BRC...
2666  Mutations in BRCA1 and BRCA2 account for the m...
2667  Mutations in BRCA1 and BRCA2 account for the m...
2668  Genetic screening of the breast and ovarian ca...
2669   Abstract  The BRCA1 gene from individuals at ...
2670  Genetic screening of the breast and ovarian ca...
2671   Abstract  The BRCA1 gene from individuals at ...
2672  Germline mutations of the breast cancer 1 (BRC...
2673   Abstract Germline inactivating mutations in B...
2674  ABSTRACT Germline mutations that inactivate th...
2675  Mutations in BRCA1 and BRCA2 account for the m...
2676  Missense substitutions of uncertain clinical s...
2677   Abstract  The BRCA1 gene from individuals at ...
2678   Abstract  The BRCA1 gene from individuals at ...
2679  Germline-inactivating mutations of BRCA1 resul...
2680  Germline mutations of the breast cancer 1 (BRC...
2681  Kinase inhibitors are accepted treatment for m...
2682   Noonan syndrome is characterized by short sta...
2683  Over 30 mutations of the B-RAF gene associated...
2684  Mutational hotspots indicate selective pressur...
2685   Abstract Activating mutations of the BRAF gen...
2686   Cardio-facio-cutaneous (CFC) syndrome is char...
2687  We have identifi ed previously undiscovered BR...
2688  We have identifi ed previously undiscovered BR...
2689  Papillary thyroid carcinoma (PTC) is the most ...
2690   Noonan syndrome is characterized by short sta...
2691  Among gynecologic cancers, ovarian cancer is t...
2692   Cardio-facio-cutaneous (CFC) syndrome is char...
2693   Cardio-facio-cutaneous (CFC) syndrome is char...
2694  The Ras/MAPK pathway is critical for human dev...
2695  The kinase pathway comprising RAS, RAF, mitoge...
2696   ABSTRACT A new model of kinase regulation bas...
2697  Selective inhibition of protein tyrosine kinas...
2698  BRAF V600R-M-D are uncommon mutations, not inc...
2699  The RAF proteins are cytosolic protein kinases...
2700   Cardio-facio-cutaneous (CFC) syndrome is char...
2701  Numerous oncogenic mutations occur within the ...
2702  Selective inhibition of protein tyrosine kinas...
2703  Genes crucial for cancer development can be mu...
2704  We have identifi ed previously undiscovered BR...
2705  Over 30 mutations of the B-RAF gene associated...
2706  Precision medicine approaches are ideally suit...
2707  Pilocytic astrocytoma, the most common childho...
2708  Genes crucial for cancer development can be mu...
2709  Lung adenocarcinomas from never smokers accoun...
2710  ERK signaling requires RAS-induced RAF dimeriz...
2711  BRAF drives tumorigenesis by coordinating the ...
2712  We have identifi ed previously undiscovered BR...
2713  Pilocytic astrocytomas (PA) are the most commo...
2714  We have identifi ed previously undiscovered BR...
2715  After whole genome sequencing of samples from ...
2716  We have identifi ed previously undiscovered BR...
2717  BRAF mutations are found in a subset of non-sm...
2718   Summary Activated RAS promotes dimerization o...
2719  Tumors with mutant BRAF are dependent on the R...
2720  Although the BRAF V600E base substitution is a...
2721  BRAF mutations are found in a subset of non-sm...
2722  Melanocytes use BRAF to activate the MAP kinas...
2723  Genes of the Raf family encode kinases that ar...
2724  Kinase inhibitors are accepted treatment for m...
2725  Genes crucial for cancer development can be mu...
2726  BRAF mutations are found in a subset of non-sm...
2727  Recently, mutations in the B-Raf gene have bee...
2728  BRAF mutations are found in a subset of non-sm...
2729  Noonan, LEOPARD and cardiofaciocutaneous syndr...
2730  The discovery of epidermal growth factor recep...
2731  Pilocytic astrocytomas (PA) are the most commo...
2732  Recently, mutations in the B-Raf gene have bee...
2733  Recently, mutations in the B-Raf gene have bee...
2734  Noonan, LEOPARD and cardiofaciocutaneous syndr...
2735  Abstract' ' ' ' Mutations in the B-Raf gene ha...
2736  Selective inhibition of protein tyrosine kinas...
2737  Of the RAF family of protein kinases, BRAF is ...
2738  The Ras/MAPK pathway is critical for human dev...
2739  Kinase inhibitors are accepted treatment for m...
2740  The NRAS and BRAF genes are frequently mutated...
2741  Noonan, LEOPARD and cardiofaciocutaneous syndr...
2742  We have identifi ed previously undiscovered BR...
2743  Abstract' ' ' ' Mutations in the B-Raf gene ha...
2744  Pancreatic acinar cell carcinomas (PACC) accou...
2745   Abstract Activating mutations of the BRAF gen...
2746  The protein kinase B-RAF is mutated in approxi...
2747  The protein kinase B-RAF is mutated in approxi...
2748  Comparative genomic hybridization (CGH) using ...
2749  Abstract' ' ' ' Mutations in the B-Raf gene ha...
2750  BRAF mutations are found in a subset of non-sm...
2751  We have identifi ed previously undiscovered BR...
2752  Genes crucial for cancer development can be mu...
2753  Pilocytic astrocytomas (PA) are the most commo...
2754  The kinase pathway comprising RAS, RAF, mitoge...
2755                                               null
2756  Over 30 mutations of the B-RAF gene associated...
2757  The mitogen-activated protein kinase (MAPK) pa...
2758  Recently, mutations in the B-Raf gene have bee...
2759  Champion KJ, Bunag C, Estep AL, Jones JR, Bolt...
2760  The RAS → RAF → MEK → MAP kinase/ERK signaling...
2761  ERK signaling requires RAS-induced RAF dimeriz...
2762  Recently, mutations in the B-Raf gene have bee...
2763  Kinase inhibitors are accepted treatment for m...
2764  Noonan, LEOPARD and cardiofaciocutaneous syndr...
2765   Cardio-facio-cutaneous (CFC) syndrome is char...
2766  ERK signaling requires RAS-induced RAF dimeriz...
2767  Aspartate 594 is the third most common BRAF re...
2768  Over 30 mutations of the B-RAF gene associated...
2769  Background and aims: KRAS and BRAF mutations o...
2770  During a clinical trial of the tyrosine kinase...
2771   Abstract The most common BRAF mutation in thy...
2772  During a clinical trial of the tyrosine kinase...
2773  Recently, mutations in the B-Raf gene have bee...
2774  Mutation screening of the breast and ovarian c...
2775  Assessing the impact of variants of unknown si...
2776  Mutation screening of the breast and ovarian c...
2777  Twenty percent of individuals with a strong fa...
2778  Mutation screening of the breast and ovarian c...
2779  Twenty percent of individuals with a strong fa...
2780  Mutation screening of the breast and ovarian c...
2781  Mutation screening of the breast and ovarian c...
2782  Mutation screening of the breast and ovarian c...
2783  Twenty percent of individuals with a strong fa...
2784  Twenty percent of individuals with a strong fa...
2785  Mutation screening of the breast and ovarian c...
2786  Mutation screening of the breast and ovarian c...
2787  Mutation screening of the breast and ovarian c...
2788  Many unclassified variants (UV) of BRCA1 or BR...
2789  The assessment of the influence of many rare B...
2790  Twenty percent of individuals with a strong fa...
2791  Twenty percent of individuals with a strong fa...
2792  Mutation screening of the breast and ovarian c...
2793   Abstract  Classification of rare missense var...
2794  Mutation screening of the breast and ovarian c...
2795  Mutation screening of the breast and ovarian c...
2796  Mutation screening of the breast and ovarian c...
2797  Twenty percent of individuals with a strong fa...
2798   Abstract  Classification of rare missense var...
2799  Mutation screening of the breast and ovarian c...
2800  The assessment of the influence of many rare B...
2801  A subset of the unclassified variants (UVs) id...
2802  Mutation screening of the breast and ovarian c...
2803  The assessment of the influence of many rare B...
2804  The assessment of the influence of many rare B...
2805  Abstract Specific BRCA1 and BRCA2 mutations re...
2806  Mutation screening of the breast and ovarian c...
2807  Purpose Rare missense substitutions and in-fra...
2808  Mutation screening of the breast and ovarian c...
2809  Twenty percent of individuals with a strong fa...
2810  Mutation screening of the breast and ovarian c...
2811  Mutation screening of the breast and ovarian c...
2812  Mutation screening of the breast and ovarian c...
2813  Twenty percent of individuals with a strong fa...
2814  Twenty percent of individuals with a strong fa...
2815  Purpose Rare missense substitutions and in-fra...
2816  Purpose Rare missense substitutions and in-fra...
2817  Mutation screening of the breast and ovarian c...
2818  Twenty percent of individuals with a strong fa...
2819   Abstract  Classification of rare missense var...
2820  Mutation screening of the breast and ovarian c...
2821  Mutation screening of the breast and ovarian c...
2822  Purpose Rare missense substitutions and in-fra...
2823  The assessment of the influence of many rare B...
2824  The assessment of the influence of many rare B...
2825  Mutation screening of the breast and ovarian c...
2826  Mutation screening of the breast and ovarian c...
2827  Mutation screening of the breast and ovarian c...
2828  Mutation screening of the breast and ovarian c...
2829  Twenty percent of individuals with a strong fa...
2830  Mutation screening of the breast and ovarian c...
2831  Mutation screening of the breast and ovarian c...
2832  Twenty percent of individuals with a strong fa...
2833  Twenty percent of individuals with a strong fa...
2834  Mutation screening of the breast and ovarian c...
2835  The assessment of the influence of many rare B...
2836  Mutation screening of the breast and ovarian c...
2837  Twenty percent of individuals with a strong fa...
2838  Mutation screening of the breast and ovarian c...
2839   Abstract  Classification of rare missense var...
2840  BRCA1 and BRCA2 mutations are estimated to be ...
2841  Twenty percent of individuals with a strong fa...
2842  Mutation screening of the breast and ovarian c...
2843  Purpose Rare missense substitutions and in-fra...
2844  Exonic variants of unknown biological signific...
2845  Twenty percent of individuals with a strong fa...
2846  Mutation screening of the breast and ovarian c...
2847  Mutation screening of the breast and ovarian c...
2848  Twenty percent of individuals with a strong fa...
2849  Twenty percent of individuals with a strong fa...
2850  Mutation screening of the breast and ovarian c...
2851   Abstract  Classification of rare missense var...
2852  Mutation screening of the breast and ovarian c...
2853  Mutation screening of the breast and ovarian c...
2854  Mutation screening of the breast and ovarian c...
2855  Mutation screening of the breast and ovarian c...
2856  Mutation screening of the breast and ovarian c...
2857  Purpose Rare missense substitutions and in-fra...
2858  Mutation screening of the breast and ovarian c...
2859  Mutation screening of the breast and ovarian c...
2860  Many unclassified variants (UV) of BRCA1 or BR...
2861   Abstract The relevance of many BRCA2 variants...
2862  Mutation screening of the breast and ovarian c...
2863  Mutation screening of the breast and ovarian c...
2864  Mutation screening of the breast and ovarian c...
2865  Mutation screening of the breast and ovarian c...
2866  Exonic variants of unknown biological signific...
2867  Mutation screening of the breast and ovarian c...
2868  Mutation screening of the breast and ovarian c...
2869  Twenty percent of individuals with a strong fa...
2870  Mutation screening of the breast and ovarian c...
2871  Mutation screening of the breast and ovarian c...
2872  The assessment of the influence of many rare B...
2873  Twenty percent of individuals with a strong fa...
2874  Twenty percent of individuals with a strong fa...
2875  Twenty percent of individuals with a strong fa...
2876   Abstract  Classification of rare missense var...
2877  Mutation screening of the breast and ovarian c...
2878  Mutation screening of the breast and ovarian c...
2879  Mutation screening of the breast and ovarian c...
2880  Exonic variants of unknown biological signific...
2881   Abstract  Classification of rare missense var...
2882  Mutation screening of the breast and ovarian c...
2883  Mutation screening of the breast and ovarian c...
2884  Mutation screening of the breast and ovarian c...
2885   Abstract  Classification of rare missense var...
2886   Abstract  Classification of rare missense var...
2887  Mutation screening of the breast and ovarian c...
2888  Exonic variants of unknown biological signific...
2889  Mutation screening of the breast and ovarian c...
2890  Mutation screening of the breast and ovarian c...
2891  Mutation screening of the breast and ovarian c...
2892  Twenty percent of individuals with a strong fa...
2893  Mutation screening of the breast and ovarian c...
2894   Abstract  Classification of rare missense var...
2895  Twenty percent of individuals with a strong fa...
2896  Mutation screening of the breast and ovarian c...
2897  Purpose Rare missense substitutions and in-fra...
2898  Mutation screening of the breast and ovarian c...
2899  Despite intense study of the neurofibromatosis...
2900  Neurofibromatosis 2 (NF2) is a tumor predispos...
2901  Neurofibromatosis type 2 (NF2) is a multiple n...
2902  Neurofibromatosis type 2 (NF2) is a multiple n...
2903  Neurofibromatosis type 2 (NF2) is a multiple n...
2904  Neurofibromatosis type 2 (NF2) is a tumour-pro...
2905  Neurofibromatosis type 2 (NF2) is a multiple n...
2906  Neurofibromatosis 2 (NF2) is a tumor predispos...
2907  Despite intense study of the neurofibromatosis...
2908  Neurofibromatosis 2 (NF2) is a tumor predispos...
2909  Current models imply that the FERM domain prot...
2910  Carcinomas of the thyroid comprise a heterogen...
2911  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2912   Abstract  Sustained activation of the stress-...
2913  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2914  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2915  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2916  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2917  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2918  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2919  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2920  One of the strategies proposed for the chemopr...
2921  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2922  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2923  Cancer genome characterization efforts now pro...
2924  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2925  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2926  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2927  Cancer genome characterization efforts now pro...
2928  Cancer genome characterization efforts now pro...
2929   Abstract  Background:  The transcription fact...
2930  One of the strategies proposed for the chemopr...
2931  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2932  The Nrf2 (nuclear factor erythroid 2 [NF-E2]-r...
2933  Hedgehog signaling is essential for tissue dev...
2934  Oligodendroglioma is characterized by unique c...
2935  Bruton’s tyrosine kinase (BTK), a member of th...
2936  The Bruton tyrosine kinase (BTK) inhibitor, ib...
2937  Bruton’s tyrosine kinase (BTK), a member of th...
2938  Alterations in nuclear factor kappa B (NF-κB) ...
2939  Nuclear factor kappa B (NF-κB) is a transcript...
2940  This study reports the identification of a nov...
2941  X-linked anhidrotic ectodermal dysplasia with ...
2942  Uveal melanoma is a neoplasm that arises from ...
2943  VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR-3 (Fl...
2944  Infantile hemangiomas are localized and rapidl...
2945  portance  Inhibition of angiogenesis is an eff...
2946   Abstract This is the case of an 84-year-old w...
2947  Angiosarcomas (AS) represent a heterogeneous g...
2948  Angiosarcomas (AS) represent a heterogeneous g...
2949  Rhabdomyosarcoma (RMS), a cancer of skeletal m...
2950  Mucosa-associated lymphoid tissue (MALT) lymph...
2951  Mucosa-associated lymphoid tissue (MALT) lymph...
2952   Abstract BRAF and NRAS are common targets for...
2953  Because of the use of alternate exons 1, mamma...
2954  A subset of growth hormone-secreting human pit...
2955  A subset of growth hormone-secreting human pit...
2956  Intraductal papillary mucinous neoplasm (IPMN)...
2957  Gastric adenocarcinoma of the fundic gland typ...
2958  The basic‐helix‐loop‐helix‐leucine zipper (bHL...
2959  Although modern treatment strategies are highl...
2960  Gastrointestinal stromal tumors (GIST) are cha...
2961  We recently identified a KITexon11mutation in ...
2962  Many studies have highlighted the critical rol...
2963  Activating mutations of the activation loop of...
2964  Most GIST patients develop clinical resistance...
2965   Abstract  Activating mutations of c-kit at co...
2966  Most gastrointestinal stromal tumors (GIST) ha...
2967  Gastrointestinal stromal tumors (GIST) are cha...
2968  c-KIT is a member of the type 3 subclass of tr...
2969  We report the case of a man with an advanced n...
2970  Gastrointestinal stromal tumors (GISTs) common...
2971  To analyze a multi-institutional series of typ...
2972  Most gastrointestinal stromal tumors (GISTs) e...
2973  Gastrointestinal stromal tumors carry in about...
2974  Gastrointestinal stromal tumors (GISTs) common...
2975  Background  In metastasized GISTs, resistance ...
2976   Purpose  KIT is the major oncogenic driver of...
2977  c-KIT is a member of the type 3 subclass of tr...
2978  c-KIT is a member of the type 3 subclass of tr...
2979  Thymomas and thymic carcinomas are rare intrat...
2980  TO THE EDITOR: I commend Drs. Freeman and Bank...
2981  c-KIT is a member of the type 3 subclass of tr...
2982  Mutational analysis of the c-kit gene in a pat...
2983  Mastocytosis is a heterogeneous group of clini...
2984  Mutations in the c-KIT receptor occur somatica...
2985  Purpose: Somatic mutations that result in the ...
2986  Purpose: Gastrointestinal stromal tumors (GIST...
2987  Activating mutations of KIT and platelet-deriv...
2988  Activating mutations of KIT receptor tyrosine ...
2989  Amplifications and mutations in the KIT proto-...
2990  Gastrointestinal stromal tumors (GIST) are cha...
2991  The pathogenesis of most gastrointestinal stro...
2992  Gastrointestinal stromal tumors (GISTs) are th...
2993  Objective:  Most patients with systemic mastoc...
2994  Gastrointestinal stromal tumors (GISTs) are of...
2995  To explore the genetic abnormalities that coop...
2996  The pathogenesis of most gastrointestinal stro...
2997  Gastrointestinal stromal tumors (GIST) are cha...
2998   Purpose  KIT is the major oncogenic driver of...
2999  Mastocytosis is a heterogeneous group of clini...
3000  KIT receptor kinase activity is repressed, pri...
3001  To analyze a multi-institutional series of typ...
3002  Gastrointestinal stromal tumors (GIST) are cha...
3003   Abstract BACKGROUND: Acral lentiginous melano...
3004  c-KIT is a member of the type 3 subclass of tr...
3005  Introduction  Mastocytosis comprises a spectru...
3006  Gastrointestinal stromal tumors (GIST) are mes...
3007   Purpose  KIT is the major oncogenic driver of...
3008  The outcome of patients diagnosed with advance...
3009  c-KIT is a member of the type 3 subclass of tr...
3010  Systemic mastocytosis (SM) is a rare disease c...
3011  Most GIST patients develop clinical resistance...
3012  We report the rare family in which cutaneous m...
3013  Context  Some melanomas arising from acral, mu...
3014  Context  Some melanomas arising from acral, mu...
3015   A 57-year-old man with gastrointestinal strom...
3016  Precision medicine uses individually determine...
3017  Amplifications and mutations in the KIT proto-...
3018  Metastatic melanoma (MM) is a highly aggressiv...
3019  Context  Some melanomas arising from acral, mu...
3020  Most GISTs can be recognized by their monotono...
3021   Purpose  KIT is the major oncogenic driver of...
3022  The duodenum as primary site for gastrointesti...
3023  Metastatic thymic carcinoma is an aggressive n...
3024  The pathogenesis of most gastrointestinal stro...
3025  The outcome of patients diagnosed with advance...
3026  Mastocytosis is a heterogeneous group of clini...
3027  Gastrointestinal stromal tumors (GIST) are cha...
3028   Melanomas belong to a heterogeneous group of ...
3029  A 48-year-old man was referred to our institut...
3030  We recently identified a KITexon11mutation in ...
3031  Mastocytosis is a heterogeneous group of clini...
3032  We report the rare family in which cutaneous m...
3033  Context  Some melanomas arising from acral, mu...
3034  Myeloproliferative neoplasms constitute a grou...
3035  The outcome of patients diagnosed with advance...
3036  The pathogenesis of most gastrointestinal stro...
3037  Systemic mastocytosis (SM) is a rare disease c...
3038  Most gastrointestinal stromal tumors (GISTs) e...
3039  Gastrointestinal stromal tumors (GISTs) common...
3040  Abstract In subsets of gastrointestinal stroma...
3041  Advanced gastrointestinal stromal tumors (GIST...
3042  Amplifications and mutations in the KIT proto-...
3043  Activating mutations in Kit receptor tyrosine ...
3044  The KIT gene is a receptor tyrosine kinase cla...
3045   Purpose  KIT is the major oncogenic driver of...
3046  Context  Some melanomas arising from acral, mu...
3047  The Ras/mitogen-activated protein kinase (MAPK...
3048  The pathogenesis of most gastrointestinal stro...
3049  INTRODUCTION  The incidence of melanoma is ris...
3050  Gastrointestinal stromal tumors (GISTs) are th...
3051  Most GIST patients develop clinical resistance...
3052  To analyze a multi-institutional series of typ...
3053  c-KIT is a member of the type 3 subclass of tr...
3054  Advanced gastrointestinal stromal tumors (GIST...
3055  Gastrointestinal stromal tumors (GIST) are cha...
3056  The pathogenesis of most gastrointestinal stro...
3057  Purpose: Gastrointestinal stromal tumors (GIST...
3058  Most gastrointestinal stromal tumors (GIST) ha...
3059  The fibroblast growth factor receptor (FGFR) c...
3060  Mediator regulates transcription by connecting...
3061  Somatic mutations in exon 2 of the RNA polymer...
3062  Uterine leiomyomas are benign smooth-muscle tu...
3063  The human thyroid hormone receptor-associated ...
3064  Inhibitors of the ALK and EGF receptor tyrosin...
3065  The majority of human pancreatic cancers have ...
3066  The majority of human pancreatic cancers have ...
3067  The majority of human pancreatic cancers have ...
3068  The majority of human pancreatic cancers have ...
3069  The majority of human pancreatic cancers have ...
3070  The majority of human pancreatic cancers have ...
3071  The majority of human pancreatic cancers have ...
3072  Since Notch phenotypes in Drosophila melanogas...
3073  The majority of human pancreatic cancers have ...
3074  The majority of human pancreatic cancers have ...
3075  The majority of human pancreatic cancers have ...
3076  The majority of human pancreatic cancers have ...
3077  Since Notch phenotypes in Drosophila melanogas...
3078  Since Notch phenotypes in Drosophila melanogas...
3079  The majority of human pancreatic cancers have ...
3080  Since Notch phenotypes in Drosophila melanogas...
3081  Activating mutations in NOTCH1 are present in ...
3082  The majority of human pancreatic cancers have ...
3083  The majority of human pancreatic cancers have ...
3084  Since Notch phenotypes in Drosophila melanogas...
3085  Since Notch phenotypes in Drosophila melanogas...
3086  Since Notch phenotypes in Drosophila melanogas...
3087  Since Notch phenotypes in Drosophila melanogas...
3088  Breast cancer is a heterogeneous disease, exhi...
3089  The Notch signaling pathway plays an important...
3090  The majority of human pancreatic cancers have ...
3091  Since Notch phenotypes in Drosophila melanogas...
3092  The majority of human pancreatic cancers have ...
3093  Glomus tumors (GT) have been classified among ...
3094  Since Notch phenotypes in Drosophila melanogas...
3095  Since Notch phenotypes in Drosophila melanogas...
3096  Squamous cell carcinomas (SCCs) collectively a...
3097  Hajdu-Cheney syndrome is a rare autosomal domi...
3098  Members of the RAS superfamily of small guanos...
3099   Choline kinase catalyzes the first rate-limit...
3100  Mutational hotspots indicate selective pressur...
3101  Many mutations in cancer are of unknown functi...
3102  Angiogenesis and metastasis are well recognize...
3103  Members of the RAS superfamily of small guanos...
3104  Members of the RAS superfamily of small guanos...
3105  Acute myeloid leukemia (AML) is a malignancy o...
3106  The genetic alterations responsible for an adv...
3107  The genetic alterations responsible for an adv...
3108   Abstract Human cancers, including breast canc...
3109  Epigenetic changes are among the most common a...
3110  ASXL1 is frequently mutated in a spectrum of m...
3111  ASXL1 is frequently mutated in a spectrum of m...
3112  Fanconi anemia (FA) is a rare chromosomal-inst...
3113  There is strong evidence that overtly inactiva...
3114  Recently, the high mobility group protein gene...
3115  Mutations in RAD51D have been associated with ...
3116  The KRAS mutation status predicts the outcome ...
3117  Activating somatic and germline mutations of c...
3118  KRAS mutations occur in one third of human can...
3119  KRAS mutational status has been shown to be a ...
3120  Abstract Introduction—Concurrent signal transd...
3121  Activating mutations of RAS are frequently obs...
3122  Detecting preinvasive lesions and accurately d...
3123  The KRAS gene is the most common locus for som...
3124   Abstract  Ras GTPases function as binary swit...
3125  Noonan syndrome (NS) is a developmental disord...
3126  Growth factor receptors activate Ras by recrui...
3127   Abstract It is thought that KRAS oncoproteins...
3128  Mutations in RAS proteins occur widely in huma...
3129  Purpose:KRAS mutations represent the main caus...
3130  Transforming mutations in NRAS and KRAS are th...
3131  Hotspot mutations of Ras drive cell transforma...
3132  The KRAS gene is the most common locus for som...
3133  Transforming mutations in NRAS and KRAS are th...
3134  KRAS mutations occur in one third of human can...
3135  To characterize somatic alterations in colorec...
3136  The effect of a series of mutations on the tra...
3137  Germ line missense mutations in HRAS and KRAS ...
3138  Activating somatic and germline mutations of c...
3139  Of the numerous oncogenes implicated in human ...
3140  The realization in the late 1970s that RAS har...
3141  The KRAS gene is the most common locus for som...
3142  A novel fluorescent guanosine 5′-triphosphate ...
3143  Germ line missense mutations in HRAS and KRAS ...
3144   Summary An alternative to therapeutic targeti...
3145  While Ras proteins are activated by stimulated...
3146  Germ line missense mutations in HRAS and KRAS ...
3147  The v-Ki-ras2 Kirsten rat sarcoma viral oncoge...
3148  In contrast to familiar role for Ras in prolif...
3149  Mutations in RAS proteins occur widely in huma...
3150  The small G-protein NRAS is mutated in 22% of ...
3151  Three quarter of endometrial carcinomas are tr...
3152   Abstract  Ras GTPases function as binary swit...
3153  The realization in the late 1970s that RAS har...
3154  KRAS mutations occur in one third of human can...
3155  The D119N mutation of p21ras was prepared by s...
3156  Cancer genome characterization efforts now pro...
3157  Cancer develops after the acquisition of a col...
3158  The KRAS gene is the most common locus for som...
3159  The KRAS gene is the most common locus for som...
3160  Hemizygous deletions are common molecular abno...
3161  Nucleophosmin (NPM1) gene has been heavily imp...
3162  Pilocytic astrocytoma (PA) is one of the most ...
3163  The Ras-RAF-mitogen-activated protein kinase (...
3164  While recurrent gene fusions involving ETS fam...
3165  We recently described oncogenic and anti-apopt...
3166  Gene fusions, like BCR/ABL1 in chronic myeloge...
3167   Noonan and LEOPARD syndromes are developmenta...
3168  Studies by comparative genomic hybridization r...
3169  Mutations leading to activation of the RAF-mit...
3170  Pilocytic astrocytomas (PAs), WHO malignancy g...
3171   Noonan and LEOPARD syndromes are developmenta...
3172  We have investigated the role that S259 phosph...
3173  Targeted cancer therapies often induce “outlie...
3174  In an shRNA screen for genes that affect AKT p...
3175  In an shRNA screen for genes that affect AKT p...
3176  Heterozygous mutations in the gene encoding he...
3177  Mutations in the hepatocyte nuclear factor (HN...
3178  Mutations in the hepatocyte nuclear factor (HN...
3179  Breast carcinoma is the leading cause of cance...
3180  Recently, a rare activating mutation of AKT1 (...
3181  Ovarian cancer is the major cause of death fro...
3182  Breast carcinoma is the leading cause of cance...
3183  Burkitt lymphoma is a germinal center B-cell-d...
3184   Abstract  The human T cell transcription fact...
3185  We describe the case of a patient presenting w...
3186  The mechanisms behind malignant progression in...
3187  Most patients with BRAFV600 metastatic melanom...
3188  Oncogenic mutations in the Neuroblastoma Rat S...
3189  The biological and clinical heterogeneity of c...
3190  Oncogenic mutations in the Neuroblastoma Rat S...
3191  Transforming mutations in NRAS and KRAS are th...
3192  KRAS mutations are the most common genetic abn...
3193  To study the oncogenic role of the NRAS oncoge...
3194  The realization in the late 1970s that RAS har...
3195  Despite recent insights into melanoma genetics...
3196  The realization in the late 1970s that RAS har...
3197  Oncogenic mutations in the Neuroblastoma Rat S...
3198  Inactivation of Ras GTPase activating proteins...
3199  Inactivation of Ras GTPase activating proteins...
3200  Phospholipase C gamma 1 (PLC gamma 1) and p21r...
3201  Phospholipase C gamma 1 (PLC gamma 1) and p21r...
3202  Lung cancer is the leading cause of major canc...
3203   Tyrosine kinase inhibitors (TKIs) elicit high...
3204  The tumor suppressor pRb plays a key role regu...
3205  The tumor suppressor pRb plays a key role regu...
3206  Rb1 is essential for normal embryonic developm...
3207  Retinoblastoma, a prototype of hereditary canc...
3208   Abstract Certain kindreds with low-penetrant ...
3209   Abstract Certain kindreds with low-penetrant ...
3210  Hereditary predisposition to retinoblastoma is...
3211   Abstract Certain kindreds with low-penetrant ...
3212  Retinoblastoma is a pediatric tumor of the dev...
3213  Quantitative multiplex PCR and genomic real-ti...
3214  Lysine-specific demethylase 5A (KDM5A), an enz...
3215  The NTRK1 gene in the q arm of chromosome 1 en...
3216  Background/Aim: The identification of addition...
3217  Tyrosine protein kinases are emerging as key r...
3218  We identified novel gene fusions in patients w...
3219   Abstract Glioblastoma multiforme (GBM) is the...
3220   Abstract Glioblastoma multiforme (GBM) is the...
3221  We identify a novel alternative TrkA splice va...
3222  Tyrosine protein kinases are emerging as key r...
3223  In this study, we utilized retroviral transfer...
3224  We identified novel gene fusions in patients w...
3225  A human oncogene formed by the fusion of trunc...
3226   Abstract Glioblastoma multiforme (GBM) is the...
3227   Abstract Background  The nerve growth factor ...
3228  Oncogenic rearrangements of the NTRK1 gene (al...
3229  Spitzoid neoplasms are a group of melanocytic ...
3230  We identified novel gene fusions in patients w...
3231  Purpose  TrkB has been involved in poor cancer...
3232  Introduction  Chromosomal rearrangements invol...
3233  Purpose  TrkB has been involved in poor cancer...
3234  The congenital fibrosarcoma t(12;15)(p13;q25) ...
3235  Pediatric high-grade glioma (HGG) is a devasta...
3236  Introduction  Chromosomal rearrangements invol...
3237  Pediatric high-grade glioma (HGG) is a devasta...
3238  Mammary analogue secretory carcinoma (MASC) of...
3239  Mitogen-activated protein kinase phosphatase-2...
3240  Lung cancer is the leading cause of cancer-rel...
3241  Lung cancer is the leading cause of cancer-rel...
3242  Lung cancer is the leading cause of cancer-rel...
3243  Collagen is an important extracellular matrix ...
3244  Collagen is an important extracellular matrix ...
3245  Lung cancer is the leading cause of cancer-rel...
3246  Collagen is an important extracellular matrix ...
3247  Introduction  Adipocytic tumors are classified...
3248  Introduction  For patients with lung adenocarc...
3249  The identification of specific chromosome abno...
3250  The identification of specific chromosome abno...
3251  Head and neck squamous cell carcinoma (HNSCC) ...
3252  Evidence exists that alterations of the genes ...
3253  Evidence exists that alterations of the genes ...
3254  Caspase-8 (Fas-associating protein with death ...
3255   Apoptosis is a form of programmed cell death ...
3256  Neuroblastoma, the most common paediatric soli...
3257  Rearrangements of the proto-oncogene RET are n...
3258  The RET protooncogene mutations responsible fo...
3259  We investigatedthe transformingactivityofthe r...
3260  Germline and somatic RET oncogene mutations ar...
3261  We investigatedthe transformingactivityofthe r...
3262  RET is a single-pass transmembrane receptor ty...
3263  Somatic RET mutations have been identi®ed in a...
3264  We investigatedthe transformingactivityofthe r...
3265  We investigatedthe transformingactivityofthe r...
3266  Activating germ-line point mutations in the RE...
3267  Mutations at aspartic acid 631 in Ret were rep...
3268  Many missense mutations in the RET proto-oncog...
3269  Oncogenic fusion of the RET (rearranged during...
3270  Germline and somatic RET oncogene mutations ar...
3271  Mutations of the RET receptor tyrosine kinase ...
3272  Many missense mutations in the RET proto-oncog...
3273  ZD6474 (vandetanib, Zactima, Astra Zeneca) is ...
3274  Many missense mutations in the RET proto-oncog...
3275  RET is a transmembrane tyrosine kinase partici...
3276  Many missense mutations in the RET proto-oncog...
3277  Mutations at aspartic acid 631 in Ret were rep...
3278  RET is a single-pass transmembrane receptor ty...
3279  Activating germ-line point mutations in the RE...
3280  Structural and biochemical characterization of...
3281  Germ line missense mutations in the RET (rearr...
3282  Many missense mutations in the RET proto-oncog...
3283  Several mutations were identi®ed in the kinase...
3284  A considerable proportion of LADCs, the most c...
3285  Germline and somatic RET oncogene mutations ar...
3286  Constitutive activation of the RET receptor ty...
3287  Germline and somatic RET oncogene mutations ar...
3288  We investigatedthe transformingactivityofthe r...
3289  Germline and somatic RET oncogene mutations ar...
3290  Objective Rearranged during transfection (RET)...
3291  We investigatedthe transformingactivityofthe r...
3292  We investigatedthe transformingactivityofthe r...
3293  RET is a transmembrane tyrosine kinase partici...
3294  Introduction  Inherited germ line activating m...
3295  Many missense mutations in the RET proto-oncog...
3296  The RET proto-oncogene encodes a receptor tyro...
3297  THE AML1 GENE IS KNOWN as the most frequent ta...
3298  Introduction  Myelodysplastic syndromes (MDS) ...
3299  The BCR-ABL fusion protein generated by t(9;22...
3300  The most frequent mutations associated with le...
3301  The most frequent mutations associated with le...
3302  Familial platelet disorder with predisposition...
3303  Introduction  Myelodysplastic syndromes (MDS) ...
3304  Familial platelet disorder with predisposition...
3305  Introduction  Myelodysplastic syndromes (MDS) ...
3306  Here we report two new RUNX1 mutations in one ...
3307  The RUNX genes have come to prominence recentl...
3308   Familial platelet disorder with propensity to...
3309  The BCR-ABL fusion protein generated by t(9;22...
3310  RUNX proteins belong to a family of metazoan t...
3311  The AML1/EVI-1 chimeric gene is generated by t...
3312  Balanced chromosomal translocations are freque...
3313  The BCR-ABL fusion protein generated by t(9;22...
3314  Introduction  Myelodysplastic syndromes (MDS) ...
3315  The RUNX gene family includes three evolutiona...
3316  Introduction  Myelodysplastic syndromes (MDS) ...
3317  Introduction  Myelodysplastic syndromes (MDS) ...
3318  The Runt-related transcription factor 1 gene (...
3319  The RUNX1/AML1 gene is the most frequent targe...
3320  The most frequent mutations associated with le...
